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ABSTRACT
MILLONI B. PATEL
HIV-1 ENV SEQUENCE AND STRUCTURE CONTRIBUTE TO BOTH CORECEPTOR
TROPISM AND SUSCEPTIBILITY TO ANTIBODY NEUTRALIZATION
(UNDER THE DIRECTION OF RONALD SWANSTROM)
HIV-1 Env is the only viral protein expressed on the surface of the virus, making Env
the sole target of selective pressure that favors mutated variants capable of evading the
immune response.  The surface subunit of Env, gp120, binds CD4 on the surface of the target
cell, followed by binding of a coreceptor, usually chemokine receptors CCR5 or CXCR4.
The virus that is normally transmitted during infection is a CCR5-using virus (R5-tropic),
which can mutate to acquire CXCR4 usage (X4-tropism) later in infection.  The coreceptor
switch is manifested in some HIV-1 subtypes, whereas other subtypes rarely make the
coreceptor switch.  env contains regions of conserved and variable sequence, and the variable
region 3 (V3) is the major determinant of coreceptor usage.  In this dissertation, we describe
subtype-specific conformational differences within the V3 region that permit coreceptor
switching in subtype B, but not in subtype C.  Furthermore, the backbone of Env interacts
with V3 to shelter it from immune pressures; when V3 is exposed, Env is hyper-sensitive to
neutralization by anti-V3 monoclonal antibodies, suggesting interactions between different
regions of Env.
In vivo coreceptor usage evolution of subtype B env variants indicates that dual-tropic
variants are always generated in the transition to X4-tropism, suggesting that coreceptor
iii
evolution begins with R5-monotropic variants, transitions into dual-tropic variants and
finally generates X4-monotropic variants.  The coreceptor switch is associated with
mutations in V3 and other areas of the env backbone, again suggesting the interaction of the
entire Env in coreceptor interaction.
Finally, the transmembrane subunit of Env, gp41, contains the epitopes of two
broadly neutralizing antibodies, 2F5 and 4E10, located in the membrane proximal external
region (MPER).  A single mutation in the MPER confers increased neutralization sensitivity
to both antibodies.  The effect of the mutation is contained to the MPER, and there is no
apparent effect on expression, folding, infection or the global structure, suggesting that the
MPER can be modified for efficient antigen presentation as part of a comprehensive vaccine
for long-term control of viremia.
Our data collectively suggest that HIV-1 env sequence and structure contribute to
both coreceptor tropism and susceptibility to antibody neutralization.
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CHAPTER ONE
INTRODUCTION
“To keep HIV out of the house, it is necessary to lock not just one door but all the doors” -
Unknown
1.1 HIV-1 epidemiology
Since its introduction into the human population, human immunodeficiency virus
type 1 (HIV-1) has infected ~1 % of the world’s adult population (100, 118).  During 2005,
an estimated 4.1 million became newly infected with HIV and an estimated 2.8 million lost
their lives to AIDS (UNAIDS, 2006).  New data suggest that HIV-1 disproportionately affects
women, especially in sub-Saharan Africa, where over 90% of HIV-1 infected persons live.
Furthermore, in 2005 approximately two-thirds of the total new infections occurred in sub-
Saharan Africa.  Anti-retroviral therapies (ART) have been available since 1987, and highly
active anti-retroviral therapies (HAART) have been available since 1997 that are able to
successfully suppress viremia below the threshold of detection.  However, no therapy or
vaccine has been developed to cure or prevent HIV-1 upon exposure.
1.2 Origins of HIV-1 in the human population
The HIV isolates are thought to represent zoonotic infections from primates.  The
2HIV-2 reservoir has been identified as the sooty mangabey Simian Immunodeficiency Virus
(SIVsm), and more recently, HIV-1 was identified as having its origins in the chimpanzee
species Pan troglodytes troglodytes SIV (SIVcpz) (77, 99).  SIVcpz is present in 29-35% of
wild living P. t. troglodytes apes in southern Cameroon and the natural range of this species
coincides with areas that are endemic with groups M (major), N (new) and O (outlier) of
HIV-1, suggesting three independent introductions of HIV-1 into the human population (77,
113, 118).  The first case of HIV-1 has been traced back to 1959, when a backdated African
plasma sample was shown to contain viral sequences in what is now the Democratic
Republic of Congo (243).  Analysis of the env genes from 150 sequences by Korber et al.
suggests that the common ancestor of the M group arose around 1931, with a confidence
interval between 1915-1941 (243).  Group M represents the pandemic HIV-1, accounting for
99% of infections, and has continued to diversify with an unprecendented genetic diversity.
This expansion of founder viruses early in the group M epidemic have consequently been
classified into nine subtypes based on sequence (179, 186, 225).  Recent analysis of HIV-1
genomes has identified recombinant viruses that have also become endemic, which are
classified as circulating recombinant forms (CRFs).  The inherent variability in HIV-1
complicates the use of a “prototypic” strain for study, therefore a centralized Group M
genome has been constructed (from consensus and ancestor genes) to use for study of
contemporary HIV-1 (63, 79, 117, 158, 159).
1.3 HIV-1 genome and life cycle
HIV-1 is part of the retroviridae family in the lentivirus genus and contains a dimeric
RNA genome that is of the positive sense.  The DNA form of HIV-1 is approximately 9.8kb
3in length, and both ends are flanked by long terminal repeats (LTR).  The proteins encoded
by the genes between the LTRs can be segregated into four groups: major structural proteins
(Gag and Env), the enzymes (Pro and Pol), regulatory proteins (Tat and Rev) and accessory
proteins (Vpu, Vpr, Vif, Nef).  The HIV virion is composed of the dimeric genome that is
closely associated with nucleocapsid (NC) and enclosed in the conical capsid structure made
up of the capsid (CA) protein.  The capsid is surrounded by a layer of the matrix (MA)
protein, which is beneath the viral membrane that contains proteins from the cell from which
it budded in addition to the viral envelope (Env) protein that is required for binding and
fusion to the next target cell.  In addition, the HIV particles contain approximately 50-100
copies of reverse transcriptase (RT), which initiates transcription of the HIV genome after
infection.
Successful DNA synthesis requires overcoming cellular restriction factors that are
important in trying to block HIV replication.  The first is APOBEC3G, a cellular cytidine
deaminase that can be packaged into the HIV virion (157).  The HIV accessory protein Viral
infectivity factor (Vif) counteracts APOBEC3G activity by binding to it and targeting it for
ubiquitination and proteosomal degradation in the virus producing cell (141).  TRIM5α is
another restriction factor, in this case targeting the CA protein early in infection.  HIV
counteracts the block by binding cyclophilin, which blocks the inhibitory effect of TRIM5α
(236).  Recent evidence also suggests that, contrary to earlier reports, HIV-1 infection does
not induce RNA interference (RNAi - a cellular restriction that is triggered by double
stranded RNA to degrade viral RNA) and also does not repress the RNAi cellular machinery
infected cells (11, 94, 136).
Upon entry, and CA shedding, the genomic RNA is reverse-transcribed into double
4stranded DNA by the viral RT.  The pre-integration complex that is already present in the
nucleus (through unclear mechanisms) contains intergrase (IN), which integrates the double
stranded DNA copy of the HIV-1 genome into the host chromosome, usually in an active
gene hotpsot (199).  The integrated (proviral) DNA is the template for transcription of viral
RNA, with the RNA start site determined by the LTR promoter region that contains
transcription factor binding sites for cellular transcription factors (168).  The initial products
of transcription are largely short RNAs with only a small percentage of full length
transcripts, some of which is spliced to generate tat mRNA.  Translation of the tat mRNA
generates Tat protein, which binds to its cis-acting enhancer, TAR, and increases processive
transcription from the HIV-1 LTR several hundred-fold (12, 58, 59).  The spliced messages
are translated like other cellular proteins (23), and the Rev protein is responsible for transport
of singly spliced and unspliced RNA transcripts to the cytoplasm for viral packaging.  Rev is
able to bind to the Rev responsive element (RRE) to shuttle RNA from the nucleus to the
cytoplasm using the cellular factor CRM1 (75, 139).  During HIV-1 assembly, cellular
proteins are recruited to the “late domain” of the Gag polyprotein, including TSG101, a
component of the cellular ESCRT-II complex (53, 209, 223).  The entire ESCRT-II complex
is thought to function directly in HIV-1 release, although a definitive role for these proteins
has not been established (53).
1.4 Structure and function of Env gp120 and gp41
The ~2.6 kb env gene of HIV-1 encodes the structural glycoprotein found on the
surface of the viral membrane that is responsible for target cell recognition and attachment.
The Env protein is composed of a heterodimer of surface envelope glycoprotein (gp120) that
5is non-covalently attached to an anchor transmembrane envelope glycoprotein (gp41).  On
the surface of HIV-1, a trimeric complex of Env heterodimers is responsible for attachment
and fusion to the target cell.  The gp120 is the most exposed element of the trimer, and
attaches to the cellular receptor CD4.  Binding of CD4 causes structural changes in gp120,
exposing previously masked epitopes, allowing binding to the cellular coreceptor (38, 42,
127, 181, 185, 203, 230).  The rearrangement after CD4 binding is also associated with large
decreases in entropy (127, 154), suggesting that CD4 binding “fixes” the previously free,
unliganded gp120 state into a single conformation that promotes coreceptor binding (237).
Further conformational changes take place upon coreceptor binding, altering the structure of
gp41, allowing insertion of the hydrophobic N-terminal of gp41 into the target cell
membrane (60), exposing two helical heptad repeats (HR1 and HR2).  HR1 and HR2 fold
back on one another to form a coiled-coil (76, 98), providing the energy to fuse the two
membranes (34, 138).  These last few steps have not been definitively resolved, and as such
are still speculative.
The gp120 subunit is composed of regions of conserved and variable sequence (C-
and V-regions, respectively) (207).  Variable domains are presumed to exist as a mechanism
to evade host immune responses and constant regions are thought to make contact with the
gp41 subunit and also make contact with viral receptors.  Both the conserved and variable
regions of gp120 are extensively glycosylated, accounting for about half of its 120kDa mass.
The glycosylations cover a large amount of the surface of gp120, most likely to modulate
immunogenicity and antigenicity, since it is the only target of neutralizing antibodies during
a natural infection.  The glycosylation sites are highly conserved and seem to contribute to
the function of Env as well.  Modification of a glycosylation in V1, or loss of a glycosylation
6in V3 changes its viral coreceptor usage (33, 40, 135, 174).  It has also been determined that
changes in glycosylation sites over the course of infection can produce neutralization
resistant virus (192, 227).  Therefore, conformational masking, sequence variability and
heavy glycosylation of conserved epitopes are important properties of Env immune evasion.
Defining the structure of the native trimer on the surface of the free virus has been
elusive.  To date, crystal structures have been obtained of gp120 (from which one or more
variable loops have also been truncated) bound to its receptor CD4 along with an anti-gp120
antibody (104, 127).  With the new generation of therapeutics being targeted at Env (such as
entry inhibitors), knowledge of the structure is more important than ever.  Three “core”
gp120 X-ray crystal structures have increased our understanding of how the protein interacts
with the target cell (36, 104, 127).  Kwong et al. first described CD4-bound gp120 as a
protein with an inner and outer domain, connected by a bridging sheet (V1/V2 and V3 loops
were truncated) (127). The inner domain is closest to the viral membrane and the outer
domain closest to the target cell, and the bridging sheet is defined as a four stranded anti-
parallel beta sheet that includes the V1/V2 stem and strands β20 and β21 from C4 (Fig. 1.1)
(adapted from Huang et al. (104)).  The two-domain CD4 molecule was found to bind via
Phe 43 to a depression in gp120 formed at the interface of the inner and outer domains (no
carbohydrates are involved) (127).  CD4 binding results in a large decrease in entropy,
exposing CD4-induced (CD4i) epitopes that are capable of binding the coreceptor.  CD4i
epitopes are composed of the conserved stem of V1/V2 and C4 and were first described after
observing that antibody binding was enhanced after CD4 binding (211).  CD4i epitopes are
created by repositioning of the V1/V2 region, which induces conformational changes within
the bridging sheet and between the sheet and the inner and outer domain. The newly created
7CD4i surfaces form the positively charged, high-affinity CCR5-binding site that can bind to
CCR5 at 100-1000X better than unliganded gp120 (128, 230).  These CD4i epitopes may not
be the most relevant target for neutralization, since the time between which CD4 binds and
CCR5 binding occurs is short and finite and a major steric restriction is imposed on accessing
the coreceptor binding site when CD4 is bound (35, 129).
Fig. 1.1.  HIV-1 gp120 core structure bound to CD4, adapted from Huang et al. (A) The V3 protrudes away
from the gp120 core, presumably to interact with the coreceptor.  (B) The gp120 is rotated 90˚ to show the
Phe43 of CD4 binding in a recessed gp120 pocket.  The bridging sheet and V3 crown are also indicated.
Further structural data was elucidated after Huang et al. crystallized the JR-FL gp120
(with an intact V3 bound to CD4) (104).  The newer structure answered more questions about
the nature of the V3 in a CD4 bound state; V3 protrudes 30 Å away from the core gp120
structure after engaging the CD4 receptor, ready to bind its coreceptor.  The extended nature
and availability to bind antibody in this conformation explains V3’s immunodominant
8character, and also the need for V1/V2 to shield it before CD4 binding.  The structure of V3
in its CD4-bound form provides a model to speculate how mutations within V3 can affect
coreceptor usage.  The final gp120 crystal structure is that of an unliganded, fully
glycosylated SIV gp120 (36).  The crystallization of unliganded gp120 is surprising given the
high entropy associated with it, and although there were many problems with it, a low-
resolution structure was solved.  When this fully glycosylated, unliganded gp120 is
superimposed to the CD4 bound core-gp120 structure (127), the outer domains are similar,
however, the bridging sheet and inner domain are considerably rearranged, presumably due
to CD4 binding.
The distribution and arrangement of Env trimers on the surface of the virus has thus
remained elusive.  However, cryoelectron microscopy tomography techniques have
suggested that virions are 109 ± 8nm in diameter and there are ~14 trimers per virus (241,
242).  Further characterization of the Env trimer suggests that only two of the three
gp120/gp41 heterodimers need to be functional to support entry (234) and only one
neutralizing antibody is required/Env trimer to prevent infection (233).  Not surprisingly, a
higher density of Env trimers on the virus surface correlates to a more efficient infection (5).
Taken together, this suggests that only a small number of neutralizing antibodies are required
to prevent infection, however, this is confounded by the poor elicitation of neutralizing
antibody in natural infection (see below).
1.5 Coreceptor binding
HIV-1 infection is directed to cells that express CD4 on their cell surface as well as a
chemokine coreceptor, usually CCR5 or CXCR4.  These coreceptors belong to a family of G-
protein coupled receptors (GPCR) that have seven transmembrane-domains, other chemokine
9receptors (ex: CCR3, CCR8, BOB and BONZO) have been implicated in infection, although
their physiological relevance in vivo remains uncertain (198).  The natural ligands for CCR5
include MIP-1α, MIP-1β and RANTES, and the only known ligand for CXCR4 is SDF-1.
These ligands are known HIV-1 antagonists for virus that use their respective receptors (18,
41).  The structures of CCR5 and CXCR4 have not been solved and were not included in any
of the gp120 structures, therefore, interactions between gp120 and its coreceptor have been
described on the basis of mutations and interactions with monoclonal antibodies (see below).
CD4 binding is directed to the interface of the inner and outer domains as described
above, whereas V3 is the major determinant of interaction with the coreceptor.  The bridging
sheet and V1/V2 are also implied in engaging coreceptor.  Sharon et al. described how MIP-
1α, MIP-1β and RANTES are structurally similar to CCR5 virus derived V3 peptides (bound
to a V3 antibody elicited by an R5-virus) and conversely, SDF-1 is structurally similar to
CXCR4 virus derived V3 peptides (bound to a V3 antibody elicited by an X4-virus) (202).
Other NMR structural studies of V3 peptides bound to antibodies also suggest the existence
of multiple conformations of the V3.  Therefore, if V3 can adopt two conformationally
distinct structures, vaccine or drug therapies directed toward the V3 region would need to be
carefully designed to specifically target one of two conformations.
1.6 V3 determinants of coreceptor binding
V3 is considered the major determinant of coreceptor usage.  Early sequence analysis
between R5-tropic and X4-tropic Envs distinguished a pattern where a basic substitution in
V3 (Lys or Arg) at position 11 and/or 25 is indicative of an X4-tropic phenotype (48, 72,
147), although a single Arg at 25 is less predictive of X4-tropism (51, 103).  Comparisons of
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R5- and X4-tropic env sequences have also implicated residues close to the C terminus of
V2, and position 440 in coreceptor usage (27, 103, 147).  Mutations in R5-tropic virus have
helped determine that many V3 amino acids can be involved in coreceptor usage; R5-tropic
virus with mutations at positions R298, N300, K305, S306, I307, R308, G312, R315, F317,
Y318, A319, R327 all decreased binding to cell surface CCR5 (47, 49, 174, 184, 226).  In
addition to V3, residues R419, I420, K421, Q422, R444, P438, R440, G441 and others in the
bridging sheet of gp120 have been implicated in coreceptor interaction (15, 47, 180, 185).
Other studies suggest the V3 region can be further dissected into two functional domains
based on their roles in binding CCR5; the V3 stem (296-305 and 321-330), which along with
residues in C4 bind to the N terminus of CCR5, and the V3 crown (306-320), which binds to
the extracellular loop 2 (ECL2) of the coreceptor (45).
Conversely, Basmaciogullari et al. reported that in an X4-tropic virus, the following
mutations all dramatically reduced binding to CXCR4: R298A, R306A, R308A, R315A,
F317A, I323A, and R327A, suggesting that basic residues may contribute to electrostatic
interactions with CXCR4 (8).  Some of these residues implicated in X4-tropism (R298,
R308, R315, R327) are conserved in R5-tropic virus, suggesting these amino acids within V3
may bind to both CCR5 and CXCR4.  Since X4- and R5-tropic Envs are organized into
nearly identical tertiary structures (126), it is easy to understand the existence of these
essential amino acids within the V3.
1.7 Nature of V3 interaction with coreceptor
Several approaches have been used to identify how V3 interacts with its coreceptor,
since a gp120-coreceptor complex has not been crystallized.  Most studies suggest that extra
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cellular loop 2 (ECL2) of the chemokine receptor reaches up to bind to residues at the crown
of V3, whereas the N-terminal of the chemokine receptor binds to residues at the base of V3
and residues in the bridging sheet (45-47).  Farzan et al. first identified the N terminus of
CCR5 as being responsible for making contacts with the base of V3 through sulfated
tyrosines, and subsequent studies have confirmed that R298 (a V3 amino acid that is
conserved in R5- and X4-tropic Envs) is important and can only bind sulfated Tyr after CD4
engagement (46, 49, 66, 67, 213).  Analysis of the gp120 crystal structures (all elucidated
with an R5-tropic virus) suggested the N-terminal of CCR5 also contacts the bridging sheet
(104, 127, 185), and that ECL2 of CCR5 contacts the base of V3, explaining how
substitutions in the bridging sheet can abrogate CCR5-meditaed infections (175).
The study of V3 interactions with CXCR4 has not been as extensive, although X4-
tropic isolates depend on the ECL of CXCR4 and the overall presence of negatively charged
and tyrosine residues (175, 213).  However, the role of glycosylations in the N-terminal of
CXCR4 for viral infectivity still remains inconclusive (32, 106, 214).  Overall, current
evidence points to a slow evolution to CXCR4 usage through mutations in V3, which may be
enhanced or compensated by non-V3 mutations.
1.8 Evolution of CCR5 usage to CXCR4 usage
For reasons that are just now starting to be understood, virus that is most frequently
transmitted by any route of infection is CCR5-using virus (144, 188, 221, 244).  It has been
suggested that this is due to the uptake of R5-tropic virus by dendritic cells at mucosal
surfaces where most transmission occurs (80, 105).  It has also been determined that CCR5
and CD4 are constitutively associated on cell membranes, so that R5-tropic viruses have the
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receptors in close proximity (232).  This is further demonstrated in the population that
contains a deletion in the CCR5 allele (Δ32), where individuals who are homozygous for this
allele are usually resistant to infection, and heterozygous individuals have delayed disease
progression (101, 137, 150).
The evolution of virus from CCR5 into CXCR4 usage occurs in 50% of subjects
infected with subtype B HIV-1, and CXCR4 usage is strongly associated with disease
progression (44, 183, 197, 198).  The cause and effect relationship between CXCR4 usage
and T-cell decline still needs to be determined, but there are reports attributing both as the
cause (107, 167).  Attempts to characterize the progression from R5- to X4-tropism have
come up with varied results.  The mutations associated with coreceptor switch were at first
attributed solely to mutations in V3 (see above); however, subsequent data suggest that the
story is more complicated (6, 112, 165, 204).  A study by Bagnarelli et al. suggests that V3
loop is the only determinant of coreceptor usage in 76% of viruses; the backbone sequence of
the virus is the determinant for other viruses (6).  Another study used CCR5/CXCR4
chimeras to show that R5-tropic virus evolve to acquire broader use of CCR5 (accompanied
by a loss of sensitivity to CCR5 ligand RANTES), suggesting that there is ongoing evolution
towards more efficient CXCR4 usage, which requires the participation of more than just V3
(175).
The final question that arises in understanding coreceptor usage is why the switch
occurs; again, the answer is not clear.  Affinity of gp120 is much higher for CCR5 (4-15nM)
compared to CXCR4 (200-500nM) (15) and although CCR5 is expressed on many cell types
including activated T cells, natural killer T cells, monocytes, macrophages, immature
dendritic cells  (8, 131), HIV-1 can only infect cells that coexpress both CD4 and the
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coreceptor.  Therefore, R5-tropic virus can only infect 10% of CD4+ T cells, whereas X4-
tropic virus can infect 85% of CD4+ T cells (19, 88).  The coreceptor switch may be
important (even with an affinity loss) in increasing host range after depletion of CCR5
positive T cells, which is now understood to take place during the acute phase of infection
(21, 142, 222).  However, if CD4+/CCR5+ T cell depletion takes place so early, how and
why does virus persist for so long in a limited host range?  There are many intrinsic obstacles
to coreceptor switching: X4-tropic virus has diminished replication compared to parent R5-
virus, evolutionary intermediates are more sensitive to both CCR5 and CXCR4 inhibitors
than parent or final virus, nonrandom changes in amino acids and glycosylations are required
to make virus X4-tropic, and finally, R5-tropic virus releases 5-10X more virus/cell (166,
189).  Further questions of the need to change coreceptor arise when we consider the 50% of
subjects that do not evolve to use CXCR4 (50, 112, 134), how are they able to utilize CCR5
efficiently enough to cause disease progression?  Finally, there are subjects who harbor two
virus populations (virus that is R5-tropic and other virus that is X4-tropic; mixed
populations), or subjects who harbor a virus population that is able to use both coreceptors
(dual-tropic).  Currently there are no in-depth evaluations of changes in vivo as the
coreceptor switch occurs, and the most informative studies involve use of coreceptor
inhibitors.  For subjects who have measureable X4-tropism, extended use of a CXCR4
inhibitor (AMD3100) shifted X4-tropic virus back to using CCR5 (64).  Another interesting
experiment where a CCR5 inhibitor (maraviroc) was accidentally administered to a subject
harboring CXCR4-using virus showed reversion to predominantly CCR5 using virus after
therapy cessation (228), suggesting an in vivo competition between virus populations for the
most efficient coreceptor (64, 228).
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1.9 Clinical correlates of phenotype prediction
The two coreceptors that are most relevant in vivo are chemokine receptors CCR5 and
CXCR4, which are important in terms of cellular tropism.  A new need to characterize the
virus coreceptor phenotype quickly and efficiently has arisen due to the advent of entry
inhibitors targeted at the coreceptors CCR5 and CXCR4.  There are two classes of inhibitors
that are in clinical trials for CCR5:  chemokine agonists that directly bind to CCR5 and
decrease surface expression of the chemokine receptor (95) and chemokine antagonists, i.e.
small molecules that act as an allosteric inhibitor to prevent gp120 from binding (4).  The
most clinically relevant molecule is maraviroc, which has recently become the first clinically
approved CCR5 inhibitor.  The strength of the drug is its ability to reduce viral loads in
subjects that exclusively harbor R5-tropic HIV-1 variants (68, 228).  Precise characterization
of virus coreceptor phenotype in vivo now has an urgent therapeutic relevance.
Thus far, the most efficient method of predicting virus coreceptor phenotype uses
biostatistical models, where V3 genotype is used as a predictor.  The original model uses the
net charge of the V3 amino acid sequence as an indicator of coreceptor usage, since there is
an increase in net V3 charge of CXCR4 using Envs (43, 174).  The 11/25 rule (a basic
substitution at position 11 and/or 25 (HXB 306 and 322, respectively) is also strongly
associated with an X4-tropic phenotype (48, 72, 74).  Furthermore, many studies have
determined that positions 429, 440, 424, and a cluster of amino acids between 190-200 are all
involved in coreceptor switching (103, 182).  Jensen et al. created a Position Specific Scoring
Matrix (PSSM) specific for subtype B V3 sequences to improve coreceptor prediction that is
84% sensitive and 96% specific (109).  PSSM are used to detect nonrandom distributions of
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amino acids at adjacent sites associated with empirically determined groups of sequences.
Often, PSSM uses background genetic variations as a baseline comparison (or null model) to
facilitate comparison of the amino acids of a sequence fragment to those of a group of
aligned sequences known to have the desired property.  Using this principle, V3 sequences
can be assigned a score; the higher the score, the more closely the sequence resembles those
of known X4 sequences.  A PSSM exists for both subtype B and C V3 sequences to predict
coreceptor use (108, 109), although the subtype C PSSM has a smaller data set to predict
from.  All of the above mentioned approaches have been used (and evaluated) extensively to
predict coreceptor use, but genotype based approaches are not 100% efficient – they are
unable to take into account evolutionary intermediates, and the models are less reliable in
predicting those variants that can concomitantly use both CCR5 and CXCR4 as coreceptors.
More recently, the combined use of V3 structural bioinformatics and V3 sequence statistical
modeling has also been used to improve coreceptor prediction (195).  Characterization of env
variants evolving in vivo will help understand the evolutionary pathway that gives rise to
CXCR4 using virus.  Currently, there is only one commercially available biological test for
functional coreceptor testing, Trofile, that involves cloning of subjects envs (229), so the
availability of a simple biological test to determine coreceptor usage will also be instrumental
for administering coreceptor based therapies.
1.10 Differences between subtype B and subtype C HIV-1
Phylogenetic analysis of HIV-1 shows that HIV-1 can be divided into three groups:
M (main), N (new), and O (outlier).  The M-group (99% of infections) is further subdivided
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into nine subtypes A-K and circulating recombinant forms (CRFs) in which each subtype has
an env nucleotide divergence of 35% between subtypes and 20% divergence within subtypes,
and up to 10% diversity within one person (124, 186, 200).  Subtype B is prevalent in North
America and Western Europe, and subtype C is the world’s most prevalent strain, found in
sub-Saharan Africa and South-East Asia, accounting for half of the new infections worldwide
(100).  As described above, subtype B virus can evolve from using CCR5 to using CXCR4 in
50% of subjects, however, subtype C is less likely to use CXCR4 during disease progression
(1, 9, 16, 17, 31, 39, 111, 169, 217).  Thus, the major subtype of HIV-1 has an evolutionary
biology that is different to most other subtypes.  The consensus V3 sequence is only different
in five amino acid positions between subtypes B and C, suggesting that sequence changes
affect structure in a way that prevents subtype C HIV-1 from using CXCR4 efficiently.
A recent study by Coetzer et al. suggests that 10% of subtype C isolates can evolve to
use CXCR4 (strongly associated with CD4+ T cell count <200 cells/mm2) and sequences that
are associated with V3 changes also have increased positive charge (not associated with V3
position 11 and/or 25 as with subtype B), insertions, loss of negatively charged residues, and
elimination of glycosylation at N301 (43, 173).  Most telling was that X4-tropic viruses
develop a mutation in at Q315, usually to Arg (subtype B consensus amino acid at this
position) (43, 173).  This suggests the presence of R315 is likely to play an important role in
CXCR4 coreceptor usage.  It has been reported that compared to subtype B R5-tropic virus,
subtype C R5-tropic virus demonstrates a slower replication profile, implying subtype C
infected subjects harbor lower viral loads during early infection (X4-tropic virus replication
is similar for both subtypes) (7, 173).  However, subtype C subjects on HAART do evolve
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X4-tropic virus, suggesting coreceptor evolution in subtype C virus is different and, perhaps,
more difficult compared to subtype B virus (39, 111).
As with subtype B, the V3 interaction of subtype C with CCR5 has been defined by
alanine scanning of V3 (210).  For subtype C, the V3 crown is dispensable for CCR5-usage
(which presumably makes contact with ECL2 of CCR5); amino acids R298A and I322A (in
the stem region) have > 90% decrease in CCR5-mediated fusion, and mutations N301A,
N302A, T303A, I325A and R326A reduce CCR5-mediated fusion modestly (210).  The
CCR5 requirements for interaction with subtype C virus have also been investigated; Tyr and
other charged amino acids in the N-terminal of CCR5 are important for virus fusion, as are
amino acids Q170, Y176, C178, K191 in ECL2.  Compared to subtype B, however, subtype
C Env is more sensitive to mutations in CCR5, suggesting a higher affinity to subtype B Env
(62, 81, 178).  Since the V3 stem and C4 are better conserved between subtype B and C, the
N-terminal interaction with both subtypes may be similar, whereas the V3 crown-ECL2
interaction is different.
It is unclear if the factors limiting subtype C CXCR4 usage are attributed to viral or
host immune factors.  Subtype B V3 structures suggest V3 can adopt alternative
conformations (202), therefore subtype C V3 may be conformationally restrained, requiring a
more complicated evolutionary pathway to acquire CXCR4 usage.  Thus, it can be conceived
that with a subtype C infection, R5-tropic virus is relatively slower replicating than its
subtype B counterpart, and subtype C X4-tropic virus is only manifested in small numbers
late in disease progression.
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1.11 Neutralizing antibodies against HIV-1 Env
An ideal vaccine candidate would elicit neutralizing antibodies in addition to cell-
mediated immunity, however, despite large efforts, progress towards an effective immunogen
has been limited.  The one large-scale clinical trial thus far was based on gp120 protein
(VaxGen) and failed to elicit neutralizing antibodies (171).  There is poor elicitation of
neutralizing antibody in natural infection, most likely due the low antigenicity and
immunogenicity of Env (the only target of neutralizing antibody) (148).  The trimeric nature
of the spike glycoproteins may also occlude many surfaces from antibody binding (227).  To
date, only five epitopes of neutralizing antibodies have been identified, since broadly
neutralizing antibodies are rarely found in natural infection: (1) the crown of the V3 region
(ex: 447-52D binds to G-P-x-R epitope) and is cross-subtype neutralizing (83) (2) the CD4
binding site (ex: IgGb12) (24) (3) the CD4-induced epitope (ex: 17b) (211) (4) the
carbohydrate moieties on the surface of gp120 (ex:2G12) (216), and (5) the membrane
proximal external region (MPER) of gp41 (ex: 2F5, 4E10 and Z13) (153, 240, 247).
All five types of antibodies have very unusual structures, which complicates the
design of an immunogen to elicit neutralizing antibodies.  2G12 is unusual in that its Fab has
a domain-swapped dimer (25).  IgGb12 has an extended heavy chain CDR3 that extends
directly out from the rest of the antibody (196).  17b has a 22 amino acid extended CDR3
(127).  In addition to having an extended CDR3, 2F5 and 4E10 antibodies also require
components of the lipid membrane and hydrophobic context of the gp41 MPER (26, 160).
Attempts to elicit other MPER directed neutralizing antibodies are problematic, since these
antibodies are autoreactive and can also bind cardiolipin and double stranded DNA (96).  The
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447-52D antibody is able to bind a conserved core sequence (G-P-x-R), and withstand lots of
variation flanking the core sequence (205).
2F5 and 4E10 are the most potent neutralizing antibodies in terms of their large
breadth and low IC50 (14, 143).  Therefore, they have been the focus as the type of
neutralizing antibody that would be optimal to generate from a vaccine.  Since antibodies
with specificity to the 2F5 and 4E10 epitope are rare in natural infection, the search to induce
this type of antibody has been initiated (239).  Use of 2F5 and 4E10 as a prophylaxis has
proved efficient in simian SIV trails, but failed when used in humans due to evolution of
neutralization escape mutants in 2G12, but not 2F5 and 4E10 (70, 71, 155, 190).  The
journey to produce an immunogen capable of eliciting neutralizing antibodies that are cross-
protective for many strains is ongoing and structural studies will help us understand the best
method for creating an immunogen.
1.12 Membrane proximal external region (MPER) of HIV-1 gp41
The MPER is a highly conserved region of the gp41 subunit of HIV-1 Env, located
adjacent to the viral membrane.  This Trp-rich region is critical for Env-mediated membrane
fusion and viral infectivity (151, 193), and contains the epitopes of antibodies 2F5 and 4E10;
Binley et al. showed that these two antibodies are the most cross-neutralizing in a study that
included many well characterized neutralizing antibodies (14). The 2F5 antibody can
neutralize 67% of isolates from a wide cross-subtype panel of Envs at a low concentration,
whereas 4E10 is able to neutralize 100% of isolates from the same panel with an even
potency at a relatively higher concentration (14).  Crystal structures confirm the 2F5 epitope
(ELDKWA) is present at amino acids 662-667 and the 4E10 epitope (NWFDIT) is present at
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amino acids 671-676 (HXB2 numbering) (26, 160).  Thus far only a handful of escape
mutations have been reported for 2F5 and 4E10; alanine scanning mutations have revealed
that resistance can occur against 2F5 with mutations at D664, K665, and W666, and against
4E10 with mutations at W672, F673, and W680 (140).  Neutralization escape in vivo to 2F5
has been found at D664 and K665; however no neutralization escape has been reported for
4E10 (246).  The high potency of these antibodies is most likely due to the location of their
linear epitopes in a highly conserved region of Env, making the MPER a natural target for
HIV-1 vaccine development.
All of the projects in this dissertation are united by the principle of determining how
both sequence and structure contribute to the overall function of HIV-1 Env.  The unique
capacity of Env to mutate and evolve contributes to its ability to overcome barriers set forth
both by the innate immune system and human-developed vaccine strategies, continuing the
process of replication and infection.  Perhaps a better understanding of how this 2.6 kb
segment of DNA is able to escape every obstacle in its path will finally help us find a cure.
CHAPTER TWO
SUBTYPE-SPECIFIC CONFORMATIONAL DIFFERENCES WITHIN THE V3
REGION OF SUBTYPE B AND SUBTYPE C HUMAN IMMUNODEFICIENCY
VIRUS TYPE 1 ENV PROTEIN
Reprinted from “Subtype-Specific Conformational Differences Within the V3 Region of
Subtype B and Subtype C Human Immunodeficiency Virus Type 1 Env Protein.”
Milloni Patel, Noah Hoffman, and Ronald Swanstrom (2007). (Journal of Virology, 2007
JVI01444-07).  In press.
22
2.1 SUMMARY
The V3 region of the HIV-1 gp120 Env protein is a key domain in Env due to its role
in interacting with the coreceptors CCR5 and CXCR4.  We examined potential subtype-
specific V3 region differences by comparing amino acid variability, and probing for subtype-
specific structure using eleven anti-V3 monoclonal antibodies (V3 mAbs).  Differences in
variability between the subtypes were most evident in the stem and turn regions of V3
(positions 9-24), with the base region being very similar in comparing the two subtypes.
Binding characteristics of V3 mAbs to subtype B JR-FL Env and subtype C BR025 Env
suggested three patterns, where each group of mAbs recognized a specific conformation- or
sequence-based epitope.  Viruses pseudotyped with Env from JR-FL and BR025 were
neutralization resistant to the V3 mAbs, although replacement of the SF162 Env V3 region
with JR-FL V3 created a pseudotyped virus that was hyper-sensitive to neutralization.  A
single mutation in V3 (H13R) made this chimeric Env selectively resistant to one group of
V3 mAbs, consistent with the mAb binding properties.  We hypothesize that there are
intrinsic differences in V3 conformation between subtype B and subtype C that are localized
to the stem and turn region, and these differences have two important biological
consequences:  first, subtype B and subtype C V3 regions can have subtype-specific epitopes
that will inherently limit antibody cross-reactivity; and second, V3 conformational
differences may potentiate the frequent evolution of R5- to X4-tropic variants in subtype B
but limit subtype C virus from using the same mechanism to evolve X4-tropic variants as
efficiently.
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2.2 INTRODUCTION
Binding of the human immunodeficiency virus type 1 (HIV-1) to its target cell is
mediated by the viral envelope glycoprotein Env.  The glycoprotein is expressed as a gp160
precursor that is proteolytically cleaved into two mature subunits, the gp120 surface protein
and the gp41 transmembrane protein.  On the surface of the virus, Env is present as a trimer
of the gp120 and gp41 heterodimer (3, 187).  When the virus binds to its primary receptor
CD4, Env undergoes conformational changes, exposing previously hidden regions and
creating new structural elements.  Env then binds to a coreceptor, usually the chemokine
receptor CCR5 or CXCR4 (61, 69, 230), which triggers further structural changes that
promote fusion to the target cell (76, 97).
The Env sequence can be viewed as being composed of regions that are relatively
constant (C1 to C5) and regions that on a population basis are much more variable (V1 to
V5) (207).  As the only viral protein expressed on the surface of the virus, Env is the sole
target of neutralizing antibodies that supply selective pressure to favor mutated variants
capable of evading the immune response (125, 227).  The V3 region is associated with
coreceptor preference and physically contacts the chemokine receptor as part of the fusion
process (61, 69, 230).  Sequence changes within V3 are often associated with a change in
coreceptor usage (103, 110, 147, 182).  During transmission of HIV-1, the virus that is
predominantly transmitted is a CCR5-using virus (R5-tropic) (188, 221, 244).   Substitutions
within the V3 region to basic amino acids at V3 positions 11 and 25 (HXB2 numbering
positions 306 and 322, respectively) are associated with CXCR4 usage (X4-tropic), as well
as other less well-defined changes elsewhere in Env (103, 147, 165).
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In approximately 50% of subjects the virus switches to CXCR4 usage, and this
coreceptor switching is associated with more rapid progression to AIDS (44, 183, 197, 198).
This phenotype is observed with subtype B virus that is found predominantly in Western
Europe and the USA.  However, in subtype C virus that predominates in Asia and Sub-
Saharan Africa, the switch from R5-tropic to X4-tropic virus is less frequent (1, 9, 16, 17, 31,
39, 111, 169, 217), although disease progression to AIDS is still evident.
Several approaches have been used to identify how V3 interacts with its coreceptor,
since a gp120-coreceptor complex has not been crystallized.  Most studies suggest that extra
cellular loop 2 (ECL2) of the chemokine receptor binds to residues in the stem/turn domains
of V3, whereas the N terminus of the chemokine receptor binds to residues at the base of V3
and/or other residues in the bridging sheet (45-47, 184).  Farzan et al. first identified the N
terminus of CCR5 as being responsible for making contacts with the base of V3 (R298)
through sulfated tyrosines (66).  In the crystal structure of a V3-containing gp120 bound to
CD4 molecule, the V3 is in a conformation found immediately before binding to the
coreceptor (104).  The CCR5-using envelope (JR-FL) contains a V3 that may act as a
“molecular hook” extending away from the core of gp120 to engage in coreceptor
interactions (104).
The V3 region is a target for antibodies, and for some virus isolates these antibodies
can be neutralizing (83).  Although there is evidence for some subtype B anti-V3 monoclonal
antibodies (V3 mAbs) neutralizing subtype C virus, the majority of subtype B V3 mAbs do
not share this attribute (245).  The limited ability of V3 mAbs to neutralize different subtypes
may be the result of differences in the structures of V3 between the two subtypes.
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In this study we examined potential conformational differences between subtype B
and subtype C V3 regions to inform our understanding of the differences in biological
properties between these lineages of HIV-1.  We used a set of V3 sequences to compare
amino acid variability between subtype B and C, and used recombinant gp120 to compare
binding of V3 mAbs.  Because we were specifically trying to understand differences between
the V3 regions of subtypes B and C, we created chimeric Envs with reciprocal V3 regions,
and also made individual mutations within V3 of amino acids that differ between subtypes B
and C.  These mutated Envs were used in binding studies and to pseudotype HIV-1 to test for
neutralization by the V3 mAbs.  We demonstrate that there are intrinsic differences in the V3
sequences of subtypes B and C within the stem and turn regions (positions 9-24) of V3.  Our
data suggest the V3 region is different between subtypes B and C, and we suggest that the
conformation of the turn region may underlie the mechanism by which coreceptor
interactions and antibody recognition differ between the two subtypes.
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2.3 MATERIALS AND METHODS
2.3.1 DATA SET
The subtypes B and C nucleotide sequences corresponding to the V3 region of gp120
(HXB2 7111-7217) were downloaded from the Los Alamos HIV Sequence Database (hiv-
web.lanl.gov).  Additional sequences collected in Malawi (Genbank accession numbers
AF153129-AF153190) were included in the subtype C data set (169).  Two methods were
used serially to create sets of epidemiologically and phylogenetically unrelated subtype B
and C sequences.  First, for groups of sequences derived from the same person, a single
sequence was randomly selected; multiple representatives of closely-linked chains of
transmissions were treated as originating from the same individual.  Sequences for which no
such epidemiological information was available were discarded.  This selection was
accomplished using a database classifying sequences by subject of origin based mainly on
annotations of Genbank references from the Los Alamos HIV Sequence Database (Brian
Foley, personal communication).  The subset of sequences from Malawi was described in
Ping et al. (169).  Next, a neighbor-joining tree with jackknife analysis was created for each
set with phylogenetic analysis using parsimony (PAUP).  The general time-reversible model
was used for the distance measure, with a gamma distribution describing the rates across sites
(other parameters were set to default values).  A total of 100 jackknife replicates were
performed.  A small number of sequences fell on branches supported by at least 50 jackknife
replicates:  all but a single sequence from each such cluster was discarded.  The final data
sets resulting from these two selection steps contained 391 and 351 subtype B and C
sequences, respectively.  The data set is available upon request.  One ambiguity to note is
amino acid 22 in our subtype B V3 data set; the LANL consensus for subtype B V3 position
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22 is Thr, however in our data set Ala was present in 53% of sequences and Thr in 46%,
further demonstrating the polymorphism at this position.  Our subtype C V3 data set was the
same as the LANL consensus for V3.
2.3.2 V3 VARIABILITY
The variability of each amino acid in alignments of each of the two sets of sequences
was characterized using Shannon entropy (201), which is calculated as:
H(x)=- ∑
i=1
m
 P(xi)logP(xi)
Here m is the number of different amino acids represented at position x, and 
€ 
P(xi)  is the
frequency of amino acid i at position x.  The maximum theoretical entropy of 
€ 
Hmax ≈ 3 at a
position would be reached in the event of equal representation of all 20 characters.  The
minimum entropy of zero is reached for positions with 100% conservation of a single amino
acid.  The significance of the difference in entropy at each position of alignments containing
subtype B and subtype C V3 sequences was calculated using a permutation test with 10,000
iterations as described in (103).  Briefly, the permutation test is a Monte Carlo simulation in
which a count is kept of the number of random regroupings of subtype B and C sequences
that results in an entropy difference equal to or more extreme than the difference resulting
from the true classification of sequences.  An uncorrected p-value is calculated as this count
divided by the number of iterations.  If no regrouping of sequences resulted in an entropy
difference as great as the true difference, a value of p < 0.001 was assigned.  We considered
positions achieving p < 0.001 as significantly different.  At this cutoff, the significance level
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of the entire analysis (or the probability that at least one of the 35 positions achieved p <
0.001 by chance) is < 0.001 x 35, or less than 0.05 (13).
2.3.3. COVARIATION
The extent of covariation between each possible pair of variable positions in the
alignments of subtype B and C V3 sequences was measured using mutual information (also
called joint entropy) as described in Hoffman et al. (102).  A position was considered
variable if at least 5% of sequences contained a non-consensus amino acid among either
subtype B or C sequences; twenty-two positions met this criterion, including positions 2, 5,
10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 32, and 34.  Positions in
V3 are numbered according to the 35 amino acid V3 consensus sequence, with the first
cysteine (HXB2 position 296) set at position 1.  Mutual information was calculated as
described (13, 120, 212).  The significance of mutual information values was calculated
using a permutation test with 105 iterations as described in Hoffman et al. (102).  There are
231 possible pairs of 22 positions; thus the significance cutoff for covariation of a single pair
was set at 0.05/231, or p < 0.0002.
2.3.4. AMINO ACID COMPOSITION
The difference in amino acid composition between subtype B and subtype C V3
sequences was calculated using Fisher’s exact test for the frequency of the consensus amino
acid versus the most common substitutions.  The significance cutoff for difference in amino
acid composition was set at 0.05/22 for the 22 variable positions analyzed, or p < 0.002.
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2.3.5 PLASMIDS    
Molecular clones of env from subtype B and C were obtained from the following:
JR-FL gp160 in the plasmid pSV (54) was kindly provided by Dr. Nathaniel Landau.  BR025
gp160 in pCR2.1 was obtained through the NIH AIDS Research and Reference Reagent
Program (NIH ARRRP) (Cat. No. 2430) from Dr. Beatrice Hahn.  BR025 gp160 in the pSV
plasmid was kindly provided by Dr. Feng Gao.  Both of these isolates have been shown to
use the CCR5 coreceptor (R5-tropic) and fail to form syncytia in MT-2 cell culture (54, 78).
2.3.6 CLONING AND EXPRESSION OF MUTANT AND WILD TYPE GP120
env genes containing modifications in V3 were generated by introducing mutations
using QuikChange site-directed mutagenesis (Stratagene, Inc.).  A Venezuelan Equine
Encephalitis (VEE) virus replicon vector (pERK, kindly provided by Alphavax, Inc.) was
used to express gp120 with a C-terminal 6X-His tag (176).  The pERK vector contains the
portion of the VEE genome encoding the non-structural proteins that are responsible for
replication.  The structural proteins were deleted and replaced by the HIV-1 gp120 of choice.
The resulting pERK plasmid was linearized by NotI digestion and used as a template for
synthesis of mRNA in vitro.  This mRNA was electroporated into mammalian cells, and the
gp120 was secreted into the culture supernatant.
2.3.7 PRODUCTION OF RECOMBINANT MBP-V3 FUSION PEPTIDE
The pc2x plasmid (New England Biolabs) was used to generate the MBP-V3 fusion
peptide.  The JRFL and BR025 V3 inserts each encompassed the V3 codons along with 5
codons upstream and downstream of V3 followed by a 6X histidine codon tag.  Both
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upstream and downstream primers were generated with BamHI restriction sites to clone into
the MCS of pc2x.  Inserts were screened using M13 reverse primers to identify V3 inserts in
the correct orientation.
2.3.8 PURIFICATION OF GP120 AND V3 PEPTIDES
Both recombinant gp120 and V3 peptides were purified using nickel beads (Ni-NTA
superflow, Qiagen) that bind the 6X histidine tag on the C-terminus of the gp120 and MBP-
V3 peptides.  The proteins were purified according to the manufacturer's protocol for
purifying from culture supernatant (gp120) or bacterial cell lysates (V3 peptides).  Eluted
protein was dialyzed into 1X PBS for storage, purity was determined by denaturing gel
electrophoresis and silver staining, and specificity was determined by western blot using an
anti-His monoclonal antibody.  Purified protein was quantified using the Bradford assay.
2.3.9 MONOCLONAL ANTIBODIES   
Anti-V3 monoclonal antibodies 19b, F3.9F, 2.1E, 2.10H, CO11, and H211 were
kindly provided by Dr. James Robinson.  All remaining anti-V3 monoclonal antibodies were
obtained through the NIH ARRRP:  447-52D (Cat. no. 4030), F425 B4e8 (Cat. no. 7626),
F425 B4a1 (Cat. no. 7625), 257-DI V (Cat. no. 1510), and 286-DIV (Cat. no. 1511).  The
following anti-Env antibodies were also obtained through the NIH ARRRP:  2G12 (Cat. no.
1476), 2F5 (Cat. no. 1475).
2.3.10 ELISA ASSAYS
Purified protein in PBS was bound to Ni-coated ELISA plates (Ni-NTA HisSorb
ELISA, Qiagen) for 2 h at room temperature.  The primary anti-V3 monoclonal antibody was
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added to duplicate wells for 2 h at room temperature, followed by washing then incubation
with an anti-human IgG HRP at a dilution of 1:2000.  For the avidity assays, different
concentrations of NaSCN were added prior to the addition of anti-human IgG HRP for 15
min at room temperature.  The assay was developed using TMB substrate and the optical
density was read on a SpectraMAX 340 ELISA reader at 450 nm every 30 s over 15 m then
analyzed using SoftMax Pro Software.  The slope of binding (OD/time) was linear for
approximately 10 m, data collected after this point were not used.  The slope was used to
infer binding efficiency.
2.3.11 PSEUDOTYPING ASSAY
To generate pseudotyped luciferase reporter viruses capable of a single cycle of
replication, we used the pNL4-3.Luc.R-E- (Luc3) plasmid, obtained from the NIH ARRRP
(Cat. no. 3418).  The Luc3 plasmid contains a frameshift within the env gene and has a firefly
luciferase gene in place of the nef gene.  We cotransfected plasmids expressing the HIV-1
gp160 with Luc3 after mixing with Fugene 6 transfection reagent (Roche Applied Science),
using 293T cells to generate viral stocks.  Supernatants were collected and assessed by p24
ELISA to normalize for infection.
2.3.12 INFECTION AND NEUTRALIZATION ASSAYS
Pseudotyped single-cycle reporter virus (100 µl) was mixed with 100 µl CCR5-
MAGI cells at 5 x 105/ml (NIH ARRRP, Cat. no. 3522) for 48 h at 37°C in a 48-well plate.
To confirm luciferase readings were in the linear range, extra wells were infected with
dilutions of the virus.  Cells were washed with 200 µl 1X PBS, then lysed with 100 µl 1X
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reporter lysis buffer (Promega).  A 50 µl aliquot of lysate was used to measure luciferase
activity using the FluorStar luminometer and analyzed with the Fluorstar software (BMG
LABTECH).  To measure neutralization sensitivity, 50 µl of virus was pre-incubated with 50
µl of antibody for 1 h at 37°C in a 48-well plate (MLV amphotropic Env-pseudotyped virus
was used to control for non-specific neutralization by the V3 mAbs).  The starting
concentrations of V3 mAb used was: 19b at 4.0 µg/ml, F3.9F at 4.0 µg/ml, F425 B4a1 at 4.0
µg/ml, F425 B4e8 at 4.0 µg/ml, 447-52D at 1.0 µg/ml, 2.1E at 4.0 µg/ml, 2.10H at 4.0 µg/ml,
H211 at 4.0 µg/ml, 257-DI V at 1.0 µg/ml, 268-DI V at 1.0 µg/ml, and CO11 at 4.0 µg/ml.
2.3.13 PHAGE DISPLAY   
The Ph.D.-12 Phage Display Peptide Library was purchased from New England
Biolabs.  The library contains a 12-mer library expressed in the minor coat protein, with a
complexity of  ~2 x 109 sequences.  Four rounds of panning were carried out by incubating
phage with a plate coated with anti-V3 monoclonal antibody.  The eluted phage was
characterized by DNA sequencing.
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2.4 RESULTS
2.4.1 CONSTRUCTION OF SUBTYPE B AND SUBTYPE C V3 DATA SETS
We first created a data set to explore sequence variation between the subtype B and
subtype C V3 regions at the amino acid level. Sequences containing insertions or deletions
(with respect to the 35 amino acid V3 consensus), and those encoding peptides with more
than a single sequence ambiguity were discarded.  All but one representative sequence from a
group of identical sequences were removed from the data set.  In addition, X4-like subtype B
sequences were eliminated from the data set to reduce the effect of variation associated with
CXCR4 coreceptor usage by removing all sequences with Arg or Lys at V3 positions 11
and/or 25 (HXB2 numbering 306 and 322) (109, 182).  This resulted in data sets of 391
subtype B V3 sequences and 351 subtype C V3 sequences; the consensus V3 sequence of
each subtype is shown in Fig. 2.1A.
2.4.2. DIFFERENCES IN V3 VARIABILITY BETWEEN SUBTYPE B AND C SEQUENCES
The subtype B V3 dataset and the subtype C V3 dataset were used to characterize the pattern
of amino acid variability in V3 using two separate analyses. First, the variability of amino
acids in the V3 region of subtype B and C sequences was characterized using Shannon
Entropy (Fig. 2.1A).  For convenience, the V3 region can be discussed as containing three
distinct domains:  the base domain (the short beta sheet adjacent to the cysteines at the start
and end of the V3 region along with the flanking region that is conserved between subtypes
B and C [residues 1-8 and 25-35, see below]); the GPG turn (positions 15-17) at the tip of the
V3 loop; and the connector or stem domain joining the base and the turn.  We examined the
concordance of the amount of variability at each position in comparing subtype B and
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subtype C V3 sequences (Fig. 2.1A).  The residues within the base of V3 had virtually
identical entropy patterns, an indication of both a similarity in selective pressure and the
quality of the data set for this analysis to be able to reveal such strong concordance.  In
contrast, residues 9-24 (stem and turn) in the center of the V3 region had very different inter-
subtype entropy patterns.  We found that there was a significant difference in entropy at
positions 2, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 22, and 24, all but one of which are present
in the stem and turn region 9-24 (Fig. 2.1A).  To quantify this difference we calculated the
average per position difference in entropy between the subtype B and C sequences,
comparing the base with the stem and turn domains (Fig. 2.1B).  There was significantly
greater per position difference in entropy in comparing subtype B and C data sets in the stem
and turn domain than in the base domains.
FIG. 2.1.  Differences in variability between subtype B and subtype C V3 regions. (A) Entropy differences at
each amino acid position in subtype B and subtype C V3 regions.  An asterisk (*) indicates significantly
different entropy between subtype B and subtype C at this position.  The consensus amino acid sequence of the
subtype B and subtype C V3 regions is indicated below. (B) Average difference in entropy per amino acid in
regions 1-8, 9-24 and 25-35 of V3.  Significance was measured using two-tailed, unpaired t-test. (C) Covarying
pairs of amino acids within subtype B and subtype C V3 regions.  Arrows indicate similar covarying pairs.
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Within positions 9-24 of both the subtype B and C V3, there is an alternating high-
low pattern of variability between adjacent amino acids within two tracts of sequence
(positions 11-13, 18-22).  This high-low pattern of variability immediately flanks the V3
GPG turn, and the pattern is shifted by one amino acid position between the subtype B and C
sequences.  For example, at position 19 of V3, variability is relatively low in subtype B
compared to subtype C.  Conversely at the adjacent position 20, variability is relatively high
in subtype B compared to subtype C.  The high-low pattern is further evidenced by the
significant difference in entropy at positions 11-13 and 18-20 (Fig. 2.1A).  We propose that
the tracts of high-low entropy contained within the stem and turn regions (positions 9-24)
that are shifted by a single residue indicate a feature of V3 structure that is divergent between
the two subtypes, resulting in two distinct conformations of the V3 region.  These results
indicate that different regions within V3 vary in the extent of sequence variability,
highlighting differences in the nature of the selective pressures, and potentially conformation,
among these different regions.
In the second analysis we considered the composition of the substituting amino acids
at the positions where variability is present (Table 2.1).  The most obvious differences are the
changes in the consensus amino acid sequence at five positions:  subtype B, H13, R18, A19,
T22, E25; subtype C, R13, Q18, T19, A22, D25 (Fig. 2.1A).  There are other differences in
the pattern of the amino acid variability in these two subtypes beyond the differences in the
consensus sequence, where patterns of substitution differ dramatically even in those positions
with the same consensus amino acid (adding detail to the entropy differences).  In this
analysis, we found that thirteen individual positions differed significantly in patterns of
substitution in comparing subtype B and C sequences (positions 5, 11-16, 18-20, 22, 24 and
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25), with only positions 5 and 25 occurring outside of the position 9-24 stem and turn region
(Table 2.1).  We interpret the differences between the subtypes as falling into three patterns,
reflecting differences in the side chain environment.  First, consistent with the entropy
differences, for nine positions, the differences between subtype B and C appears to be driven
by the relative conservation in one subtype but detectable diversity in the other subtype
(positions 11-16, 18, 20, and 24).  However, even with the differences in conservation,
positions 13 and 24 also appear to differ in composition.  Second, two positions, 5 and 25,
display significant diversity in both subtypes, but the composition of the diversity differs.
Finally, positions 19 and 22 display reciprocal patterns in comparing the two subtypes.  Since
the side chains for these two positions are near each other in the subtype B gp120 structure
(104), this suggests that these positions may be flipped, but are otherwise serving analogous
roles in the two subtypes.  Overall, the majority of differences in polymorphism are
contained in the stem and turn region, again suggesting that structural differences in the V3
region between subtypes B and C are located here, while more minor differences exist in the
base residues 1-8 and 25-35.
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TABLE 2.1. Percentages of amino acids present at each V3 position in subtype B and C
1a 2 3 4 5* 6 7 8 9 10 11* 12* 13*
Cb T R P N N N T R K S I H R
84c 77c 96 99 77 64 83 73 78 96 97 54 63 94
I (11) I (10) L (2) R (<1) S (11) G (19) R (16) R (11) G (21) G (3) V (3) V (29) P (16) G (5)
V (5) H (<1) T (<1) G (7) S (11) E (8) M (15) N (11) K (<1)
A (4) L (<1) H (3) Q (4) S (4) T (<1)
>9
9
>9
9
G (<1)
>9
7
>9
9
>9
9
>9
8
T (3) T (3)
14* 15* 16* 17 18* 19* 20* 21 22* 23
I G P G R Q A T F Y T A T
68 95 88 98 73 99 90 68 75 97 90 88 46 98
M (15) A (4) W (5) R (<1) K (11) R (<1) T (6) A (28) W (11) L (1) F (6) F (11) A (53) T (1)
L (14) L (2) E (<1) S (6) V (2) V (2) L (8) H (3)
V (2) W (<1) Q (6) I (4)
99 99
V (<1)
10
0
G (3)
>9
5
 24* 25* 26 27 28 29 30 31 32 33 34 35
G E D I I G D I R Q A H C
97 79 38 54 95 95 90 92 85 79 88 83 87 83
E (2) N (13) D (30) E (17) V (4) V (5) T (4) T (4) N (13) N (20) K (7) K (6) Y (12) Y (15)
D (3) Q (14) G (14) V (4) V (3) R (4) E (5)
K (2) A (7) A (7) E (1) R (3)
G (5) N (3)
N (3)
>9
9
>9
8
>9
8
>9
9
>9
9
a V3 amino acid (HXB2 296-331).
b Consensus amino acid at this position.
c Left column represents subtype B sequences, right column represents subtype C sequences (all numbers are
rounded to the nearest percentage, polymorphism representing < 2% of sequences have been omitted for all
positions except 17, 18, and 24).
* Positions that have significantly different patterns of substitution using Fisher’s exact test (p < 0.002).
TABLE 2.2.  Mutual information scores of each covariation pairing
Subtype Position 1 Position 2
Mutual
information
score
p-valuea
5 27 0.067 0.00001
11 13 0.078 *
13 18 0.096 *
14 16 0.108 *
14 18 0.093 *
14 20 0.158 *
14 25 0.120 *
18 20 0.091 0.00001
19 20 0.063 0.00009
20 25 0.171 *
22 25 0.077 *
B
24 27 0.047 *
10 12 0.093 0.00001
12 19 0.086 0.00001C
12 24 0.079 0.00001
a An asterisk (*) denotes p <  0.00001.
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2.4.3 DIFFERENCES IN COVARYING PAIRS WITHIN V3 BY SUBTYPE
The same subtype B and C V3 data sets were used to determine if covarying pairs were
present within the V3 region (where covariation is defined as the likelihood of one amino
acid in V3 being substituted at a higher than expected frequency in the presence of a second
substitution).  Covarying pairs were measured by mutual information (Table 2.2) (102).
There are more covarying pairs in subtype B compared to subtype C V3 (Fig. 2.1C), which is
consistent with the higher overall entropy in subtype B compared to subtype C V3.  All of the
covarying pairs in subtype C V3 appear to have a corresponding pair in subtype B V3 that is
shifted by one amino acid (Fig. 2.1C, arrows).  For example, in subtype B V3, a covarying
pair occurs between amino acids 13 and 18, and in subtype C V3 a corresponding pairing
occurs between amino acid 12 and 19.  Similarly, an 11-13 pair in subtype B mirrors a 10-12
pair in subtype C.  This apparent shift in the positions of covarying pairs reinforces the idea
of inter-subtype differences and is consistent with the shift in alternating entropy values.  The
chemical interactions implied by these covarying pairs (either direct or indirect) are very
different in comparing the two subtypes.  This suggests either that the potential for variability
is creating apparent linkage between these positions (but with restricted specificity), or that
these chemically disparate pairs are having an indirect effect on structure rather than
recreating compatible chemical interactions.
2.4.4 DIFFERENCES IN THE BINDING OF ANTI-V3 MONOCLONAL ANTIBODIES TO SUBTYPE
B AND C V3 PROTEIN SEQUENCES
We next tested the hypothesis that conformation, driven by the sequence differences, differs
between subtype B and C V3 regions.  We assembled a panel of 11 anti-V3 monoclonal
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antibodies (V3 mAbs) that had been isolated from subjects naturally infected with subtype B
HIV-1 (Table 2.3), and tested them for binding to the subtype B and subtype C V3 protein
sequences to assess differences in binding.  In our initial assessment of the V3 mAbs we
measured binding to subtype B and C V3 sequences in two contexts:  recombinant gp120
containing the V3 sequence, and a V3 peptide.
The JR-FL Env was used to represent subtype B as it contains the consensus V3
amino acid sequence for a subtype B R5-tropic virus.  We used the BR025 Env to represent
subtype C, which contains three amino acids changes compared to the JR-FL V3 region:
H13R, R18Q and T22A (this Env protein does not contain the subtype C consensus at the
polymorphic positions T19 and D25).  Using a V3 mAb concentration that saturated the
subtype B gp120 or V3 peptide, we determined the total amount of each V3 mAb that was
able to bind to the same amount of subtype C gp120 or V3 peptide.  As shown in Fig. 2.2A,
all of the V3 mAbs bound to JR-FL gp120; however, when binding to BR025 gp120
occurred (4/11 mAb), it was decreased 40-55% compared to JR-FL.  These results suggest
that either all of the antibodies recognize epitopes that are disrupted by the amino acid
differences between subtype B and C V3 sequences, or that these amino acid differences
affect the overall conformation of V3 in such a way as to impact the binding of all of the V3
mAbs.
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FIG. 2.2.  Differences in binding of V3 monoclonal antibodies to subtype B and C V3 protein sequences. (A)
Binding to wild type JR-FL and BR025 gp120. (B) Binding to wild type JR-FL and BR025 V3 peptides. (C)
Binding to chimeric JR-FL and BR025 gp120.  The slope value indicates OD/time (measured in 30 second
intervals); thus, a slope of 0.1 indicates an OD of 0.4 at the two minute time-point (background is 0.03 +/-
0.009).  There is no data (ND) available for V3 mAb H211. (D) Binding to wild type JR-FL and BR025 gp120
in the presence of NaSCN. (E) Binding to wild type JR-FL and BR025 V3 peptides in the presence of NaSCN.
Group 1 mAbs are represented by squares (), Group 2 by triangles () and Group 3 by circles ().  JR-FL
symbols are closed and BR025 symbols are open, the black and grey identifies mAbs in the same Group
binding to the same subtype.
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In an effort to determine the effect of the backbone Env structure on the binding of
mAbs to the subtype B and C V3 sequences, we created V3 peptides as a heterologous fusion
protein to use in the binding same assay.  As shown in Fig. 2.2B, all of the V3 mAbs were
able to bind to the JR-FL V3 peptide, and nine out of eleven of the V3 mAbs bound to
BR025 V3 peptide.  This result suggests that these antibodies can bind the sequence in the
BR025 Env protein but that it is conformationally constrained when in gp120 relative to the
peptide and in a way that is distinct from the subtype B Env protein.  The remaining two
antibodies (268-DIV and CO11) did not bind to either the BR025 gp120 or the BR025 V3
peptide, suggesting that for these V3 mAbs the sequence differences in the subtype B and
subtype C V3 regions disrupt the epitope.
In comparing the patterns of binding to the gp120 proteins and the V3 peptides we
were able to place the mAbs into three groups:  Group 1 mAbs which were able to bind both
the subtype B and C gp120 and peptides; Group 2 mAbs which could bind the subtype B but
not the subtype C gp120 while being able to bind both V3 peptides; and Group 3 which were
able to bind only to the subtype B gp120 and peptide.  It should be noted that these groupings
do not necessarily define groups of distinct epitopes since even two antibodies binding the
same region may favor interactions with different subsets of amino acids for the binding.
We further investigated the interactions of V3 mAbs to gp120 and V3 peptides by
measuring avidity using antibody elution with the chaotropic agent sodium thiocyanate
(NaSCN) (Fig. 2.2D-E).  We used six mAbs (2 from each group) to test avidity and found
varying degrees even within each group.  However, the patterns of antibody avidity were
similar for both the JR-FL gp120 and V3 peptides, with slightly tighter binding (i.e. higher
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NaSCN elution concentration) consistently seen in the context of binding to gp120 (Fig
2.2D).
Binding to the subtype C BR025 V3 sequence did reveal significantly different
binding avidities for these antibodies (Fig 2.2E).  The Group 1 antibody 19b bound with a
low avidity to BR025 gp120, similar to its binding to the subtype B gp120.  However, the
higher avidity binding to subtype B gp120 seen with the other Group 1 antibody F3.9F was
lost and showed a much lower avidity binding to the subtype C gp120.  These two antibodies
behaved similarly in the context of binding the V3 peptides.  A similar pattern of binding was
seen with the two Group 2 antibodies in binding to the V3 peptides:  the antibody with low
avidity to the subtype B sequence (2.1E) was similarly low binding to the subtype C
sequence, and the antibody that bound with high avidity to the subtype B sequence (447-
52D) bound with low avidity to the subtype C V3 sequence.  Thus the binding detected to the
subtype C V3 sequence was of lower avidity, although the detection of binding by the Group
2 antibodies to the subtype C V3 peptides was in the context of a trend toward lower avidity
of binding to the peptides versus gp120.
2.4.5 CHIMERIC ENV BINDING TO ANTI-V3 MONOCLONAL ANTIBODIES
We next used gp120 protein but now made chimeras with respect to the V3 sequence
to assess the contribution of the Env backbone on the V3 conformation.  Chimeric Env
proteins were created with BR025 V3 in the JR-FL backbone (JRFL-V3BR025), and the reverse
(BR025-V3JR-FL), and these gp120 proteins were analyzed for mAb binding.  We again found
distinct patterns of binding to the wild type and chimeric Env proteins (Fig. 2.2C).  Similar to
binding the subtype B and C gp120s, the Group 1 mAbs were able to bind both chimeric
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gp120 proteins, while the Group 2 and 3 mAbs were able to bind only the chimeric protein
with the subtype B V3 sequence.  We conclude that the Group 1 mAbs bind to V3 in a way
that is not affected by the gp120 backbone, while the Group 2 mAbs bind to a structure
created by the subtype B V3 sequence and is not impacted by the gp120 backbone, and the
Group 3 mAbs bind an epitope that is defined by the subtype B V3 sequence.
We next determined the impact of individual substitutions in V3 on mAb binding.
JR-FL and BR025 V3 sequences contain three amino acid differences (JR-FL = H13, R18,
T22 and BR025 = R13, Q18, A22).  Positions 13 and 18 were singly and doubly mutated in
the two gp120 proteins and the two V3 peptides, resulting in a panel of four JR-FL Envs
(Fig. 2.3A).  The binding of the mAbs to these mutants fell into the same three groups
described above, with a representative member of each group shown in Fig. 2.3.  The Group
1 antibodies displayed a binding pattern that indicates the subtype B backbone can
accommodate changes in the V3 region at position 13 (H13R) and/or position 18 (R18Q)
(Fig. 2.3B).  Binding to the equivalent peptides showed no differences (Fig. 2.3C).  Group 2
antibodies required an R18 residue in order to bind JR-FL gp120, but binding was not
significantly affected by the H13R change (Fig. 2.3B).  Similarly, binding to the V3 peptides
was reduced for those peptides carrying the R18Q mutation (Fig. 2.3C).  Finally Group 3
antibodies (268-DI V and CO11) could only bind WT JR-FL gp120 and peptides (Fig. 2.3B
and C), demonstrating again that H13 and R18 are both required for binding to this group of
antibodies.
Subtype C V3 mutants also defined three distinct patterns of mAb binding.  We
repeated the above experiment using mutants of the subtype C gp120 protein and V3 peptide
(Fig. 2.3A).  For Group 1 mAbs, the H13 residue enhanced binding to Env, but the R18
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mutation reduced binding in the subtype C backbone regardless of which amino acid was
present at position 13 (Fig. 2.3D); however, none of these mutations affected binding to the
V3 peptides (Fig. 2.3E).  This suggests that R18 has a specific interaction in the subtype C
backbone that affects the conformation of the V3 region.  For Group 2 mAbs, the Q18R did
not rescue significant binding but the R13H/Q18R double mutant did allow binding (Fig.
2.3D), again suggesting a specific interaction of R18 with the BR025 backbone that could be
rescued with H13.  Peptide binding was affected only by the R13H mutation (Fig. 2.3E),
supporting the idea that the poor binding of the Q18R mutant in the subtype C gp120 had a
structural basis.  Finally, the Group 3 antibodies behaved in the same way toward both the
subtype B and the subtype C peptides and the gp120 proteins; both H13 and R18 were
required for binding to this group of antibodies, likely defining key aspects of the epitope
(Fig. 2.3D and E).  Avidity experiments were also carried out for the pairs of antibodies from
the different groups using the V3 peptides with individual mutations at positions 13 and 18
(data not shown).  The binding patterns were complex for these pairs of antibodies, showing
increases or decreases in avidity that appeared more antibody specific than group specific.
2.4.6 V3 MONOCLONAL ANTIBODY EPITOPE MAPPING
The patterns of V3 mAb binding to the chimeric subtype B and subtype C Env
proteins suggest that antibody interactions with V3 can occur in distinct ways.  Limited
epitope data are available on the V3 mAbs used in this study (Table 2.3).  Therefore, we used
a phage display system to identify elements of the epitopes for the V3 mAbs.  An M13 phage
display library with 12-mer inserts (complexity of 2.7 x 109 sequences) was used in a
panning strategy with a subset of the mAbs.  After four rounds of panning, phage DNA was
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isolated and sequenced.  For the most part the selected phage did not give either
homogeneous sequences or even highly enriched V3 homologs, however V3-like sequences
were detected in the selected phage pools and these are presented in Table 2.3.  Sequences
selected by the three Group 1 antibodies all included a Pro and additional sequences to the N
terminus that are consistent with the region around H13 being an important part of the
epitope, similar to the placing of the F425 B4e8 epitope in the crown region by scanning
mutagenesis (163).  The three Group 2 antibodies all selected sequences that included a Gly-
Pro, similar to the region bound as seen in the structure of 447-52D (205), and consistent
with R18 playing a critical role in binding of the Group 2 mAbs.  Finally, the two Group 3
mAbs also selected sequences similar to the V3 turn that included a His followed by turn-like
amino acids, again consistent with H13 and R18 being critical elements of their epitopes.
TABLE 2.3.  Epitopes of V3 monoclonal antibodies previously characterized
Group
Anti-V3
monoclonal
antibody
Previously reported
epitopea
Epitope determined
by phage displayb
Epitope
sequenced/total
number of sequences
19b Non linear: -I----G--FY-T IH-GP--A 1/10
257-DI V KRIHI K-I--GP 2/20
F3.9F Unknown ND -
F425 B4a1 Base of V3 loop ND -
One
F425 B4e8 I---P-R (F/L)H(K/Q)P 5/20
447-52D Crown of V3: GP-R ND -
2.1E Unknown PGR(A/T)F 2/10
2.10H Unknown H-GPGR 1/10Two
H211 Unknown GR-FY 3/20
268-DI V HIGPGR (F/L)H(K/Q)P 7/20Three CO11 Unknown H-GPGR 11/20
a These epitopes are based on previously published data (28, 29, 86, 87, 149, 163, 205, 245).
b ND = no data was generated for this V3 mAb epitope by phage display.
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FIG. 2.3.  Binding of anti-V3 monoclonal antibodies with progression of V3 from JR-FL to BR025 and the
reverse. (A) Sequence of mutant V3 gp120s generated. (B) Binding of JR-FL gp120 with the progression of V3
from JR-FL to BR025. (C) Binding of JR-FL V3 peptide with the progression of V3 from JR-FL to BR025. (D)
Binding of BR025 gp120 with the progression of V3 from BR025 to JR-FL. (E) Binding of BR025 V3 peptide
with the progression of V3 from BR025 to JR-FL.
2.4.7 NEUTRALIZATION OF SUBTYPE B VIRUS BY EACH GROUP OF ANTIBODIES
Using wild type virus, we measured the ability of all of the V3 mAbs to neutralize
virus pseudotyped with the JR-FL Env protein at high antibody concentrations.  Even though
all the V3 mAbs were able to bind to JR-FL V3 (as V3 peptides or JR-FL gp120), we found
that the JR-FL Env pseudotype was resistant to neutralization by all of the V3 mAbs tested
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(Fig. 2.4).  JR-FL is known to be a relatively difficult virus to neutralize (30, 84, 224);
therefore we also tested neutralization by the V3 mAbs against SF162, a subtype B Env that
is sensitive to neutralization (122).  As demonstrated in Fig. 2.4, six out of the ten V3 mAbs
tested were able to neutralize SF162 at least 50% at mAb concentrations that failed to
neutralize JR-FL.
In an attempt to account for the three amino acid differences between the SF162 and
JR-FL V3 region (H13T, T22A, and E25D), we created a chimeric SF162 with a JR-FL-like
V3 sequence (SF162-V3JR-FL) to further differentiate neutralization ability of the V3 mAbs.
Virus pseudotyped with this chimeric Env protein was hypersensitive to neutralization by all
of the V3 mAbs.  One explanation for the apparent hypersensitivity of SF162-V3JR-FL is that
in the context of Env the V3 region of SF162 Env is more accessible than JR-FL Env and the
JR-FL V3 sequence is preferred for binding, making this Env chimera especially sensitive to
neutralization.  The differential neutralizing activity of 19b, 2.10H, and the two Group 3
viruses in comparing SF162 and SF162-V3JR-FL suggests an important role for one or more of
the three V3 amino acids that differ between these two Env proteins in defining the epitope
and/or structure.  We confirmed these differential sensitivities to neutralization by
determining IC50 values for six of the mAbs (two from each group) for JR-FL, SF162, and
SF162-V3JR-FL; the hypersensitivity to SF162-V3JR-FL was seen as was the resistance of JR-FL
and the intermediate sensitivity of SF162 (data not shown).
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FIG. 2.4.  Neutralization of subtype B Envs by various monoclonal antibodies; the same antibody concentration
was used to neutralize each of the Envs. The wild type JR-FL was neutralization insensitive compared to wild
type SF162. When the JR-FL V3 was inserted into SF162 Env, this Env was neutralization hyper-sensitive.
Addition of a H13R to the hyper-sensitive SF162-V3JR-FL had altered sensitivity to Group 3 antibodies. There is
no data (ND) available for neutralization of JR-FL by V3 mAb 257-DI V.
The hypersensitivity of SF162-V3JR-FL allowed us to compare the neutralization
sensitivity of an infectious mutant, H13R (Fig. 2.4).  We found that the two Group 3
antibodies were completely dependent on H13, and the virus was no longer sensitive to
neutralization in the presence of R13, the same pattern observed for their binding to either the
gp120 proteins or the V3 peptides (Fig. 2.3).  In contrast, the other mAbs retained their
neutralizing activity to this mutant, again consistent with the binding data (Fig. 2.3).
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2.5 DISCUSSION
The V3 loop plays a central role in the life cycle of HIV-1 but, like other regions of
the genome, displays subtype-specific sequence variation (119, 121, 152).  We are interested
in the possibility that these sequence differences can impact virus biology in a subtype-
specific way.  Using the analysis of sequence variability and the binding of V3-specific
monoclonal antibodies, we have found evidence for subtype-specific differences in the V3
region of subtype B and subtype C HIV-1 Env.  We believe these differences contribute to
differences in the biology of subtype B and subtype C HIV-1, and that these differences need
to be understood in greater detail, as this will contribute to mechanistic insights into the role
of the V3 region in virus replication and the host immune response.
 The V3 region of Env is responsible for interacting with the coreceptor at the initial
stages of infection (61, 69, 230).  This vital contact with an invariant host protein suggests
that the sequence of V3 must be constrained in order to preserve the ability to interact.
Consistent with this expectation, the V3 regions of the different subtypes are relatively
similar among the HIV-1 subtypes, although subtype-specific differences exist (121, 205).
The V3 base.  Mutagenesis across the V3 region has been used to define functional
constraints (8, 46, 49, 66, 67, 210, 213).  Ala substitutions that affect binding to a peptide
representing the N terminus of CCR5 showed that the positions critical for binding included
positions near the Cys residues (up to position 8 on one side and starting at position 26 on the
other side; (45)).  The CD4i class of antibodies as a group tend to be negatively charged and
these are thought to mimic the same N-terminal domain of CCR5 in binding to the bridging
sheet of gp120 (184, 185, 231).  These observations have led to a model where part of the
interaction with CCR5 involves the negatively charged (with sulfated tyrosines) N terminus
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of CCR5 interacting with the bridging sheet and the base region of V3 (66, 184, 185).  The
expectation of sequence conservation is also consistent when considering the eight residues
proximal to the terminal Cys residues in the base region, they are essentially identical in
amino acid composition and entropy when comparing subtype B and subtype C V3 (Fig.
2.1).  This conservation can be seen over greater phylogenetic distances, as only one position
on each side of the base is chemically distinct in comparing HIV-1 and SIVcpz.  Thus both
the sequence conservation and the similarity in entropy between subtype B and subtype C V3
sequences in this base region (positions 1-8 and 25-35) are consistent with a V3 interaction
with an invariant cellular protein.
Entropy, covariation, and structure.  We considered the relationship between
entropy and side chain orientation (using the V3 region of the JR-FL V3 structure (104)),
classifying residues as "up" (2, 9, 13, 18, 20, 21, 26, 32, 34), "down" (3, 6, 12, 14, 19, 22, 30,
31, 33) or in the plane of the V3 main chain ("flat" 5, 7, 8, 10, 11, 23, 25, 27, 29) (excluding
Cys, Pro, and Gly residues).  At 15 of 18 positions there was a concordance of residues
pointing either up from the plane of the V3 and having higher entropy or down from the
plane and having lower entropy.  The exceptions were positions 21, 22 (an Ala/Thr mixture),
and 26.  In the plane of V3, eight residues point away from the main chain and six of these
have high entropy.  Thus the higher entropy positions to a large extent make up one face and
the sides of V3.  Other evidence pointing to the importance of residues present on the faces
of V3 comes from the ability of another anti-V3 monoclonal antibody 2219 to bind to three
different V3 peptides in two distinct conformations, revealing binding that is dependent on
the sets of residues present on the face of V3 (206).  This study also showed that the base of
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the V3 region is conserved among the three peptides and the dynamic portion of V3 is the
flexible stem and turn region (206).
Given that the patterns of covariation differ between subtype B and subtype C V3
sequences it is not surprising that the positions that show covariation are among the most
variable and discordant positions, which lie in the stem and turn domains (Fig. 2.1, Table
2.2).  Subtype B V3 has more covarying pairs compared to subtype C V3, however, the
subtype C pairs appear to have corresponding pairs in subtype B that are shifted by one
amino acid position.  This is similar to data presented in several other studies (13, 82, 120)
that determined covarying pairs in subtype B V3 did not generally covary in subtype C V3,
and there are fewer overall covarying pairs in subtype C V3.  However, only one covarying
pair overlapped between our study and the others (subtype B V3, positions 19 and 20) (82).
Other studies on variability within the V3 region found that there is considerably less
variability in subtype C V3 as compared to subtype B V3 (82, 169), also suggesting an
alternate structural characteristic of the two subtypes.  A major difference in the previous
studies of covariation was the inclusion of V3 sequences that used CCR5 and/or CXCR4 as
coreceptor.  We have previously shown that much of V3 variability in subtype B is
associated with sequences that have features indicative of X4 tropism (103, 147, 169, 182),
prompting us to attempt to exclude X4 sequences from this current data set.  Thus at least
some of the reported covariation may reflect the coreceptor switch or other methodological
differences between the studies.  Although we excluded X4 sequences, not all viruses
capable of using X4 have sequence changes in V3 (109), raising the possibility that some of
the excess variability in the subtype B data set may still reflect the presence of X4 viruses.
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Differences between subtype B and subtype C.  The consensus sequence identity,
the similarity in entropy patterns, and the extensive similarity in the amino acid substitution
patterns of residues 1-8 and 25-35 in comparing subtype B and subtype C are in striking
contrast to the values of these same measures for residues 9-24.  Only positions G15 and
G17, in the GPG turn, Y21 and T23 approximate the level of similarity between the subtype
B and subtype C sequences that is seen in the base region.  In the current model of V3
binding to CCR5, the stem and turn domains of V3 interact with the extra-cellular loops of
CCR5 (66, 184, 185).  Perhaps the strongest experimental evidence for this interaction comes
from the occurrence of mutations affecting the coreceptor switch from CCR5 to CXCR4
within the stem and turn domains (47, 49, 174, 184, 226), and the appearance of mutations
selectively in the stem domain that confer resistance to CCR5-binding inhibitors of HIV-1
that enhance affinity for CCR5 (123, 238).  If subtype B and subtype C V3 sequences interact
with the CCR5 extra-cellular loops in an equivalent way then the GPG turn residues and
positions Y21, and T23 could represent a conserved motif for this interaction.  However, if
other residues are involved then the functionally equivalent interactions with CCR5 likely
occur through different molecular interactions, or at least starting with conformationally
distinct V3 regions.
The idea that these sequence differences give rise to conformational differences is
supported by the pattern of binding for eleven V3 monoclonal antibodies used in this study.
The eleven antibodies fell into three groups with distinctive patterns of binding.  All of the
V3 mAbs were able to bind both JR-FL gp120 and V3 peptide (as an example of subtype B);
in addition the Group 1 and Group 2 antibodies were able to bind to the V3 peptide of BR025
(as an example of subtype C) indicating that for these two groups of mAbs the sequence
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changes in V3 by themselves did not restrict the ability of the mAb to bind, although binding
did occur with generally lower avidity.  In contrast, the Group 3 mAbs required H13 and R18
for binding as both necessary and sufficient for binding in either the BR025 or JR-FL
backgrounds and for either gp120 or peptide forms of the V3 region.  All of the Group 1
mAbs bound JR-FL gp120 although binding of some V3 mAbs was reduced in JR-FL-
V3BR025.  In the same manner, only Group 1 mAbs were able to bind to BR025 gp120, but
both Groups 1 and 2 V3 mAbs were able to bind to BR025 V3 peptides.  This suggests that
conformational constraints in gp120 prevent Group 2 antibodies from binding to V3 at a
detectable level, although the sequence can be bound in the peptide form.
The progression of V3 from a subtype B-like sequence to a subtype C-like sequence
showed that Group 1 mAbs are promiscuous in their ability to bind to gp120, suggesting
restrictions to binding are conformation based for this group.  Consistent with the known
447-52D epitope, the other Group 2 mAbs were very sensitive to the presence of an Arg at
position 18.  Finally, the Group 3 mAbs were similar to the Group 2 mAbs in being sensitive
to a position 18 Arg, but also similar to the Group 1 mAbs which in at least some
circumstances are sensitive to the amino acid at position 13.  Thus all three groups of mAbs
appear to be dependent on different combinations of amino acids in and around the V3 stem
and turn.  We conclude that most V3 mAbs are likely targeted to the distal turn region of V3,
which is responsible for making contact with the extra-cellular loops of the coreceptor.
Our data demonstrate that different V3 mAbs are sensitive to different patterns of
sequence change within the turn region.  While such groupings are most easily explained by
assuming a single epitope within a group, we cannot draw this conclusion from our data since
subtle differences in antibody recognition and avidity likely play significant roles that our
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data do not fully explore.  The five differences in the consensus sequence of the two subtypes
occur at positions 13, 18, 19, 22 and 25.  Positions 13 and 18 are both different in
composition between subtypes B and C in that subtype B is variable and subtype C is
conserved.  For positions 19, 22, and 25, composition is less variable: both positions 19 and
22 are polymorphic for Ala and Thr in subtypes B and C, and position 25 is composed of Asp
and Glu ~ 70% in both subtypes.  Therefore, we argue that the substitution/composition
patterns indicate that positions 13 and 18 are more likely to be responsible for defining
structure in the turn of both subtype B and C.
Epitope accessibility and antibody binding.  Neutralization is dependent on both
epitope recognition and accessibility of an antibody to the epitope.  Differences between the
neutralization sensitivity of primary isolates and lab-adapted strains have been well
documented (14), in particular for both CD4-induced epitopes and V3 antibodies.  Our use of
JR-FL and SF162-V3JR-FLa represents an extreme example of this phenomenon.  All of the V3
mAbs were able to bind to JR-FL Env, but were not able to neutralize JR-FL Env.  The
insertion of the JR-FL V3 into the SF162 Env backbone generated a virus that was
hypersensitive to neutralization.  Pinter et al. have shown that the JR-FL V1/V2 domain is at
least one determinant of the occlusion of the V3 loop (170). It is also possible that the V1/V2
region of subtype C can obscure V3, this would be an alternative explanation of the inability
of Group 2 V3 mAbs to bind to BR025 gp120, even though they can bind BR025 V3
peptides.  We were also able to reproduce the epitope sequence requirement for gp120 and
peptide binding seen for the Group 3 antibodies by showing the H13R mutation in the
context of the chimeric SF162-V3JR-FLa pseudotyped virus was resistant to neutralization even
at high antibody concentrations.
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The role of V3 conformation in coreceptor switch.  Sharon et al. previously
suggested that the V3 region adopts two alternate conformations (202), depending on
whether the virus is R5-tropic or X4-tropic for subtype B HIV-1.  However, a number of
studies have reported that X4-tropic viruses are much less frequent in people infected with
subtype C HIV-1 (1, 9, 16, 17, 31, 39, 111, 169, 217).  We hypothesize that the V3 region in
a subtype B R5-tropic virus is less constrained and is able to accommodate mutations that
allow X4-tropism.  Conversely, the subtype C virus V3 region is conformationally restricted,
limiting the potential for evolution to usage of the CXCR4 coreceptor.  This suggestion is
supported in part by studies of X4-tropic subtype C virus that suggest that the appearance of
Q18R (a subtype B-like amino acid) is associated with the emergence of X4-tropic virus
variants (43).  Three other sequence differences are noteworthy in comparing subtype B and
C with regard to the coreceptor switch.  First, a change at position H13 has been implicated
as a contributing determinant to CXCR4 usage, in some cases with a H13R change (37, 147);
however R13 is the consensus sequence for subtype C as an R5 virus.  Second, Env position
R440, which is in the C4 domain and lies under the V3 region in the gp120 structure,
frequently evolves to a polar or acidic side chain in subtype B X4 viruses (27, 103, 146, 147);
in subtype C HIV-1 position 440 has Glu as the consensus amino acid.  Finally, the
consensus amino acid at V3 position 18 is Gln in subtypes A, C, D, F, G and various CRF’s.
One plausible explanation for these differences is that an early subtype C-like X4 variant
(R13, R18, E440) was a progenitor of the subtype B lineage and involved a phenotypic
reversion to CCR5-tropism in part through changes at positions 13 and 440.
Vaccine implications.  We examined the binding of eleven human monoclonal
antibodies; all eleven appear to bind to the distal turn domain based on the sensitivity of
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mutations in the stem and turn domains and on (incomplete) phage display selection (Table
2.3).  While it is possible that other antibodies will be identified that bind to the conserved
base region, our data would suggest this is not a region of the protein that is readily
immunogenic in the context of gp120, at least in comparison to the turn domain.
Data that could help predict if the generation of anti-V3 neutralizing antibodies by a
vaccine would be effective are still incomplete.  It is uncertain if a cocktail of V3 mAbs used
as a prophylaxis would be beneficial in the face of an infection.  Therapeutic administration
of V3 mAbs (as was done with the neutralizing antibodies 2F5, 4E10 and 2G12 (215)) would
be helpful to assess their potential to impact an infection.  Antibodies raised against virus
containing the GPGR turn sequence are also less likely to cross-react within a panel of virus
containing the GPGR or GPGQ turn sequence (44%) than antibodies raised against a virus
containing the GPGQ turn sequence (71%) (85).  There are a few subtype B-raised anti-V3
monoclonal antibodies that are cross-reactive with subtype C virus containing the GPGQ turn
sequence, with some potency (83, 85).  However, this is the exception rather than the rule, as
numerous other studies have shown that the GPGR turn sequence is required for subtype C
virus neutralization by V3 mAbs raised against subtype B virus (14, 43, 205).  To date, the
only broadly neutralizing V3 mAb characterized requires a GPxR motif at the turn region and
does not bind or neutralize subtype C virus (that usually contain a GPGQ turn sequence)
(205, 245).  The differences in antibody binding that we observed in this study suggest that
the design of V3-based immunogens would benefit from a consideration of subtype-specific
sequence differences, however the occlusion of V3 in many primary isolates must be
acknowledged as representing a significant limitation for this target.
CHAPTER THREE
IN VIVO CORECEPTOR USAGE EVOLUTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
ENV VARIANTS
Milloni Patel generated env amplicons and CMV-stitched Envs, Morita Pagan and Gretja
Schnell contributed to the HTA analysis of subjects.  The data is currently being used to
prepare a manuscript for peer-reviewed publication.
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3.1 SUMMARY
The coreceptor switch that occurs in HIV-1 is associated with disease progression is
impacted by many host and viral factors.  In this study we used single genome amplification
to characterize envs present in vivo in chronically infected HIV-1 individuals to assess both
the V3 genotype with the PSSM coreceptor prediction tool and the env phenotype to
determine biological coreceptor usage.  Our results suggest that the PSSM prediction was
valid for 84% of envs, and phenotypic characterization of HIV-1 subject envs suggests that
coreceptor evolution begins with R5-monotropic variants, transitions into dual-tropics
variants and then generates X4-monotropic variants (no subjects harbored R5- and X4-tropic
variants without the presence of dual-tropic variants).  This transition is associated with an
expansion in the number of V3 variants during the dual-tropic phase of coreceptor usage (p <
0.02), suggesting the evolution of multiple Env variants from which only the fittest virus is
able to establish itself as a Env variant capable of efficient coreceptor usage.  We propose
using our functional phenotype test as the basis for characterizing subject Envs in vivo for the
purpose of administering coreceptor-based therapeutics.
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3.2 INTRODUCTION
Entry of human immunodeficiency virus type 1 (HIV-1) into a target cell is initiated
through the interaction of the viral envelope glycoprotein (Env) and specific target cell
receptors.  Env is composed of a trimer of two subunits; a gp41 transmembrane protein that
anchors Env into the viral membrane and a gp120 subunit that is surface exposed.  During
infection, the gp120 subunit attaches to the cellular receptor CD4, causing structural changes
in gp120, notably stabilization of the outer domain of gp120, and exposes previously masked
epitopes, including the V3 region, allowing binding to the cellular coreceptor, usually
chemokine receptors CCR5 and CXCR4.
There have been many studies on the most efficient method of predicting virus
coreceptor phenotype using genetic algorithms based on HIV-1 subject sequences before and
after coreceptor switching.  The original rule uses the net charge of the V3 amino acid
sequence as an indicator of coreceptor usage, since there is an increase in net V3 charge of
CXCR4-using Envs (22, 73, 174).  The 11/25 rule (a basic substitution at position 11 and/or
25 (HXB 306 and 322, respectively) is also strongly associated with an X4-tropic phenotype
(48, 72-74, 182).  Furthermore, other studies have determined that positions 429, 440, 424
(located in the gp120 bridging sheet) and a cluster of amino acids between 190-200 are all
involved in coreceptor switching (103, 182).  Jensen et al. created a Position Specific Scoring
Matrix (PSSM) specific for subtype BV3 sequences to improve coreceptor prediction; the
PSSM is 84% sensitive and 96% specific (109).  PSSM are used to detect nonrandom
distributions of amino acids associated with empirically determined groups of sequences.
Often, PSSM uses background genetic variations as a baseline comparison (or null model) to
facilitate comparison of the residues of a sequence fragment to those of a group of aligned
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sequences known to have the desired property.  Using this principle, V3 sequences can be
assigned a score; the higher the score, the more closely the sequence resembles those of
known X4 sequences.  These methods have been used extensively to predict coreceptor use,
but V3 genotype-based modeling is limited in identifying evolutionary intermediates with
less of a sequence signal, limiting the utility of the coreceptor prediction.
The evolution of virus from CCR5 usage into CXCR4 occurs in 50% of subjects and
CXCR4 usage is strongly associated with disease progression (44, 116, 183, 197, 198, 200).
The cause and effect relationship between CXCR4 usage and T-cell decline still needs to be
determined, but both are attributed as the cause (107, 167).  Recent data implies other regions
of env, particularly V1/V2 are also involved (6, 27, 37, 90, 112, 164-166, 204) in coreceptor
switching.
The sensitivity of Envs to CCR5 and CXCR4 targeted entry inhibitors has often been
used as a measure of Env fitness, evidencing an increased sensitivity to both inhibitors during
the coreceptor switching phase (164, 204).  This is complemented by studies using
CCR5/CXCR4 chimeras to show that R5-tropic virus evolve to acquire broader use of CCR5
(175).  Overall, the data suggest ongoing coreceptor evolution towards more efficient
CXCR4 usage, where V3-specific mutations are not the only changes required for coreceptor
switching.
A new need to characterize the virus coreceptor phenotype quickly and efficiently has
arisen due to the advent of entry inhibitors targeted at coreceptor binding, which have the
advantage of targeting extracellular HIV-1.  A CCR5-specific entry inhibitor, maraviroc
(Pfizer), was recently licensed for clinical use, thus the need to know both what coreceptor
phenotype a subject possesses and the changes that are occurring in vivo that might change
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coreceptor phenotype with a simple biological assay are critical.  Currently population-based
methods of coreceptor tropism are being used to assess coreceptor usage, most notably the
commercially available Trofile assay (Monogram Biosciences) (229).  However, Trofile and
other similar tests require cloning of entire virus quasispecies to generate coreceptor
phenotypes, overlooking minor variants that may be important to identify.  This became
important during the recent clinical trial of maraviroc when they accidentally enrolled a
subject who harbored a minor CXCR4-using virus population and generated a massive
outgrowth of X4-tropic virus while on treatment (228).  Sequencing of quasispecies is limited
since it cannot distinguish between populations of variants that individually use CCR5 or
CXCR4 as coreceptors versus a dual-tropic variant that can use both coreceptors versus a
dual-tropic variant mixed with one or both monotropic variants.  All the phenotyping
methods described above rely on cloning a PCR fragment of the V3 region or full-length env,
and recent methods have also combined PCR amplification with direct ligation to CMV
promoters to generate functional Envs (10, 114, 218).  However, without the use of limiting
dilution PCR to amplify envs, there is the possibility of PCR recombination, which is known
to occur frequently during HIV-1 amplification with multiple templates (65, 114, 137, 235).
Here we characterize env genes isolated from HIV-1 infected subjects to understand
mutations that arise along the evolutionary pathway from CCR5- to CXCR4-usage.  We used
limiting dilution PCR to amplify full-length env genes from blood plasma in the absence of
PCR-mediated recombination, and subsequently did sequence and phenotype analysis of the
env genes for coreceptor usage.  This is the first large scale study of intra- and inter-subject
genotype-phenotype data sets with gp120 sequences (n = 412), that identifies some of the
limitations of V3 genotype-based coreceptor predictions.  We have used a simple
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phenotyping assay that does not involve env cloning, for a more time-, labor- and cost-
effective method to characterize subject coreceptor usage.  We have also sequenced V1-C5
of gp120 to look at associated mutations in the env gene that are involved in coreceptor
switching.
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3.3 MATERIALS AND METHODS  
3.3.1 STUDY PARTICIPANTS
The 46 subjects in the present study were part of AIDS Clinical Trials Group study
359 (93), a randomized, partially double-blind, multifactorial study.  Subjects enrolled in this
trial were therapy-experienced, had taken indinavir for >6 months and were experiencing
virologic failure.  Subjects selected for this study had 4,760 - 491,310 HIV-1 RNA copies/ml.
All subjects were considered to be chronically infected.
3.3.2 RNA EXTRACTION  
RNA was extracted from 140 µl of blood plasma using the QIAamp viral RNA
minikit as per manufacturers instructions (Qiagen) with a final 55 µl elution volume.
Samples with viral RNA loads of <10,000 copies/ml were concentrated by centrifugation of 1
ml of blood plasma at 25,000  g for 1.5 h at 4 ˚C before RNA extraction.  The virus pellet
was resuspended in 140 µl of its supernatant, and RNA was extracted as described as above.
3.3.3 RT-PCR FOR V3-HTA
For V3-HTA analysis, the V3 region of the HIV-1 env gene was reverse transcribed
and PCR amplified by using the One-Step RT-PCR system (Qiagen) as per manufacturer’s
instructions.  Five µl of isolated RNA was used in the reaction, with primers HIVV3F (5’-
gaatctgtagaaattaattgtacaagaccc-3’) and HIVV3R (5’-ccattttgctctactaatgttacaatgt-3’)
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3.3.4 V3-BIOTIN-HTA   
The V3 Mut-1 probe plasmid (10 µg) (Schnell et al., manuscript in preparation) was
digested with BamHI (60 µl total volume) followed by a fill-in reaction with 4 nmol Biotin-
11-dGTP (PerkinElmer), 0.05 mCi [α-35S]-dATP (PerkinElmer), 20 units of the Klenow
fragment of DNA polymerase I, and 0.6 µl of 1M DTT.  The reaction was incubated for 15
minutes at room temperature followed by heat inactivation for 10 minutes at 80°C.  The V3
Mut-1 probe was released from the vector by PstI digestion, and the total reaction volume
was brought up to 100 µl using TE buffer.  Unincorporated nucleotides were removed using
a ProbeQuant G-50 micro column (GE Healthcare).  The resulting single-stranded 35S-,
biotin-labeled probe was used for V3-HTA, as described in Nelson et al. (156).  Briefly, an
aliquot of 8 µl of unpurified RT-PCR product was combined with 1 µl of probe, 1 µl of 10X
annealing buffer (1 M NaCl, 100 mM Tris-HCl [pH 7.5], 20mM EDTA), and 0.1 µM
concentrations of HIVV3F primer, in a total volume of 10 µl.  The probe and duplex PCR
products were denatured at 95˚C for 2 min, followed by a 5-min incubation at room
temperature to allow formation of heteroduplexes.  Heteroduplexes were resolved on a non-
denaturing 12 % polyacylamide gel (acrylamid-bisacrylamide [37:5:1]) in 1X Tris-borate-
EDTA buffer.  Dried gels were exposed to X-ray film and a phosphorimaging screen
(Molecular Dynamics). The relative abundance of each detected variant was determined by
calculating the percent abundance of each V3 variants using ImageQuant software
(Molecular Dynamics).
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3.3.5 SEQUENCE ANALYSIS OF HTA VARIANTS
V3-HTA variants were sequenced as described (Schnell et al., manuscript in
preparation).  Briefly, the dried HTA gels were aligned with the exposed autoradiography
film, and the desired labeled bands were excised from the gel.  The gel fragment was
incubated in 120 µl; 500 mM NH4OAc, 0.1% SDS, 0.1 mM EDTA at 37°C overnight.
Streptavidin-coated Dynabeads (Invitrogen) were used to purify the heteroduplex DNA, and
then to remove the probe strand from the query strand.  The purified query strand DNA was
amplified with the Platinum Taq DNA Polymerase High Fidelity PCR kit (Invitrogen) as per
the manufacturer’s instructions, using 2 µl DNA and the PCR primers HIVV3F and HIVV3R
(described above).  The PCR cycling conditions were one cycle of 94°C for 5 min; 25 cycles
of 94°C for 30 s, 55°C for 30 s, 68°C for 1 min; one cycle of 68°C for 7 min.  The amplified
PCR products were then sequenced using primers V3SeqF (5’-
tgtagaaattaattgtacaagacccaacaa-3’) and V3SeqR (5’-tttgctctactaatgttacaatgtgcttgt-3’).
Five subjects (15, 69, 110, 350, and 411) contained V3 variants generated by HTA
that were not detected by SGA, which were sequences that exhibited 2, 5, 8, 11, or 12 amino
acid differences compared to any variants detected by SGA.  Excluding subject 110 V3
variants (contained a variant with 2 amino acid changes), the lack of sequence homology in
the remaining HTA V3 sequences suggests these may have been subject to contamination
during the gel extraction phase, especially if variants were close together on the HTA gel
(this is true of subjects 15, 69 and 350).  Subject 411 V3 variants by HTA are confusing, they
do not align with any neighboring V3 variants and suggest contamination during PCR
reflected in the V3 variants.
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3.3.6 RT-PCR FOR SGA
Fifty microliters of eluted viral RNA, diluted to 10 copies/µl, was combined with
1.25 µL primer B8936dn (20 µM) (5’-ttgctacttgtgattgctccatgt-3’), 10 µM dNTPs, 11.25 µl
dH20 and heated at 65˚C for 5 min to allow primer to anneal.  cDNA was synthesized in a
total volume of 100 µl using Superscript III RT (Invitrogen, Carlsbad, CA), according to
manufacturers instructions (with the exception of increasing the final concentration of SSIII
RT to 50 units/ml) at 55 ˚C for 1 hour, followed by inactivation of RT at 70 ˚C for 15 min.
The template RNA was degraded by adding 1µ l RNase H to each reaction.  cDNA
synthesized from subject plasma was diluted and subjected to RT-PCR to generate full-length
env amplicons.  Briefly, High Fidelity Platinum Taq (Invitrogen) was used to amplify env
using primers B5853up (5’- tagagccctggaagcatccaggaag-3’) and B8936dn in the first round
of amplification.  PCR conditions were as follows: one cycle of 94˚C for 2 min; 35 cycles of
94˚C for 15 sec, 55˚C for 30 sec, 68˚C for 4 min; one cycle of 68˚C for 10 min.   The same
PCR reaction was set up for the second round of PCR, this time using nested primers
B5957up (5’-gatcaagctttaggcatctcctatggcaggaagaag-3’) and B8904dn (5’-
agctggatccgtctcgagatactgctcccaccc-3’).  PCR conditions were as follows for the second round
of PCR: one cycle of 94˚C for 2 min; 45 cycles of 94˚C for 15 sec, 55˚C for 30 sec, 68˚C for
4 min; one cycle of 68˚C for 10 min.  All PCR products were electrophoresed on an agarose
gel to determine reactions with PCR products of the correct length.
3.3.7 SEQUENCING OF ENV
Multiple primers spanning the V1-C5 env gene were used to sequence both strands of
env amplicon DNA.  See Table 3.1 for primers sequences and locations.  The V3 variants
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were considered different if they contained two or more differences in amino acid than any
other variant in the subjects overall V3 population.
Table 3.1. Primers used in coreceptor analysis
Amplification of outer SGA
B5853 (upstream) 5’-tag agc cct gga agc atc cag gaa g-3’
B8936 (downstream) 5’-ttg cta ctt gtg att gct cca tgt-3’
Amplification of nested SGA
                   B5957 (upstream) 5’-gat caa gct tta ggc atc tcc tat ggc agg aag aag-3’
B8904 (downstream) 5’-agc tgg atc cgt ctc gag ata ctg ctc cca ccc-3’
Sequencing of SGA from V1-C5
V1 forward 5’-tta tgg gat caa agc cta aag cca tgt gta-3’
Reverse 15 5’-ctg cca ttt aac  agc agt tga gtt ga-3’
Forward 15 5’-cag cac agt aca atg tac aca tgg aa-3’
7320 downstream 5’-gca tta caa ttt ctg ggt ccc ctc c-3’
7514 upstream 5’-gaa agt agg aaa agc aat gta-3’
 8056 downstream 5’-ttc caa ggc aca gca gtg gtg-3’
V3 L4 5’-gaa tct gta gaa att aat tgt aca aga ccc-3’
Generating a CMV promoter
CMVenv (upstream) 5’-agt aat caa tta cgg ggt cat tag ttc at-3’
CMV + env (downstream) 5’-ctt ctt cct gcc ata gga gat gcc taa agc ttg atc-3’
Generating a functional CMV promoter-stitched env amplicon
CMVenv (upstream) 5’-agt aat caa tta cgg ggt cat tag ttc at-3’
envM_hmRNA (downstream) 5’-tgg gtg gct ctg aaa aga gcc ttt ggg ctg ctg gct cag ctc gtc tca ttc ttt c-3’
3.3.8 PHYLOGENETIC ANALYSIS
V1-C5 sequences of gp120 for each of the amplicons were aligned using PHYML
(PHYlogenetic inferences using Maximum Likelihood) – a simple, fast algorithm to estimate
large phylogenies by maximum likelihood (http://atgc.lirmm.fr/phyml) (91, 92) was used to
generate phylogenetic trees.  The maximal 500 bootstraps were performed for each set of
sequences, and the random reference strain AY357410 (Genbank) was used as an internal
control.
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3.3.9 PSSM PHENOTYPE
The online Position Specific Scoring Matrices (PSSM) coreceptor prediction tool
(http://ubik.microbiol.washington.edu/computing/pssm/) (109) was used to predict
coreceptor phenotype for each env amplicon that was generated based on V3 sequence.
3.3.10 GENERATION OF CMV PROMOTER DRIVEN ENV AMPLICON
The SGA-derived env amplicon was directly stitched to a CMV promoter to generate
a functional linear env amplicon, modified from Kirchherr et al. (114).  The CMV promoter
was amplified from a functional subtype B env clone Z13.05 (data not shown) using primers
CMVenv (5’ -ag taa tcaa t tacggggtca t tag t tca t -3’ )  and  CMV+env (5’ -
cttcttcctgccataggagatgcctaaagcttgatc-3’) to create a 3’ end that is complementary to the 5’
end of SGA-derived nested env amplicons.  Overlapping PCR, using the upstream primer
CMVenv and a downstream primer (env_hmRNA) containing a histone mRNA stabilization
signal (5’-tgggtggctctgaaaagagcctttgggctgctggctcagctcgtctcattctttc-3’), was used to generate a
linear CMV promoter-stiched env amplicon.
3.3.11 CORECEPTOR PHENOTYPING ASSAY
A single cycle pseudovirus containing the SGA Env amplicon was generated by co-
transfecting 293T cells in triplicate with the linear CMV-promoter env amplicon and an env-
deficient HIV-1 backbone that had luciferase expressed in place of Nef (Luc3, ARRRP, Cat.
No. 3418).  The supernatant was collected at 48 hours and used to infect U373 MAGI cells
co-expressing CD4 and CCR5 (ARRRP, Cat. No. 3522) or CXCR4 (ARRRP, Cat. No. 4036)
in quadruplicate wells in a 96-well format.  MAGI cells (100 µL, 2 x 105 cells) were infected
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with 100 µl of supernatant for 48 hours and then lysed with 50 µl Reporter Lysis Buffer
(Promega).  The lysate was frozen, thawed and then measured for luciferase activity.  The
value reported for each amplicon is the fold-activation over background (using average RLU
of quadriplicate wells) compared to Luc3 only transfection.
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3.4 RESULTS
3.4.1 MULTIPLE V3 VARIANTS PRESENT IN VIVO    
V3-HTA analysis frequently reveals the presence of multiple variants in late-stage
infection.  The subject cohort consisted of HIV-1 seropositive participants from the AIDS
Clinical Trial Group, protocol 359 (ACTG359) (93).  The 46 participants included in this
study was a subset of subjects previously characterized to include subjects with a range in the
number of V3 variants (M. Pagan, manuscript in preparation).  The trial entry time point
plasma sample was used for all assays.  The viral load for each subject ranged from 4,760 to
491,310 viral copies/ml, and the CD4 count ranged from 4.5 to 694 cells/ml (Table 3.2).  The
V3-HTA (156) was performed using RT-PCR products from all 46 participants plasma-
derived viral RNA.  The V3-HTA probe was slightly modified compared to previous studies
from our group, changing the sequence of the 3’ primer binding site to limit PCR
amplification of the probe sequence.  An example of the V3-HTA analysis are shown in Fig.
3.1; here subjects 120, 123, and 130 had a single V3 variant, and subjects 110, 128, and 138
had multiple V3 variants.  Overall, out of the 46 total subjects, 21 subjects (46%) had single
variants, and 25 subjects (54%) had multiple variants (range 2-5 variants).
The relative abundance of each V3 variant present in all subjects was determined
(Table 3.2).  Out of the 25 subjects with multiple variants, 20 had one dominant variant with
an abundance of 53-97%.  Three subjects had incomplete sequence data and two subjects did
not show a dominant variant.  Overall, the V3-HTA revealed that V3 variants can coexist in
vivo, and as expected, a dominant variant is usually present in the population.
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FIG. 3.1.  V3-HTA sample analysis of subjects
3.4.2 PHENOTYPE OF ENVS BASED ON PSSM
Each of the V3-HTA bands was excised and sequenced to identify V3 sequences
associated with each band.  The Position Specific Scoring Matrix (PSSM) (109) was used to
generate a coreceptor phenotype prediction associated with the HTA-extracted V3 sequences.
The subjects were then separated into groups based on PSSM coreceptor prediction; there
were sixteen subjects with CCR5 only V3 variants, eleven subjects with CXCR4 only V3
variants and nineteen subjects with mixed (both CCR5 and CXCR4) V3 variants (Table 3.2).
We determined the average number of V3 variants associated with each subject group: the
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CCR5 only group was significantly different compared to the mixed group (p <0.02, two-
tailed t-test), the CXCR4 group approached significance when compared to the mixed group
(p <0.09), and there was no significant difference when comparing the CCR5 and CXCR4
only groups.  A major limitation of the PSSM coreceptor prediction is its inability to predict
if a particular V3 variant is able to use both CCR5 and CXCR4 as coreceptors (dual-tropic).
Nonetheless, PSSM predictions of the HTA-extracted V3 variants suggest that this cohort of
subject contains a variety of coreceptor phenotypes, providing a quality subject subset to be
used for further genotype-phenotype assessment.
TABLE 3.2.  Characteristics of subjects and their Env variants by PSSM coreceptor predictions
PSSM
coreceptor
prediction a
Subject CD4 count(cells/ml) b
Viral load
(RNA
copies/ml) b
Number
of V3
HTA
variantsc
Percentage of
most
abundant
variant by
HTA
Total number
of SGA env
amplicons
generated
Number
of V3
SGA
variantsd
22 233.5 17921 1 100 4 2
59 505 12909 3 29 22 4
65 134 54267 1 100 6 5
110 236.5 32471 2 87 14 1
120 50 18907 1 100 5 1
123 180 14413 1 100 8 2
128 154.5 148974 2 62 6 2
130 381.5 33926 1 100 11 1
173 282 40839 2 100 6 2
202 313 29949 1 97 16 2
251 120 56706 2 100 12 1
280 523 45349 1 100 7 1
285 316.5 46324 1 - 9 1
392 369 102947 1 37* 11 1
437 229.5 9704 2 100 8 2
R5 only
(n = 17)
449 694 44535 1 100 9 1
Average - 295 44384 1.41 - - 1.82
39 528 80082 1 100 10 2
63 212.5 97409 3 74* 10 2
67 357.5 13240 1 100 7 4
70 75 5355 2 60 7 2
135 233.5 13727 1 56 18 2
138 192.5 161870 4 42 16 4
170 268 106709 3 81 15 3
172 245 422748 3 92 6 3
204 91.5 149052 1 100 7 1
Mixed
(n = 19)
273 12 491310 2 70 9 2
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310 99 48331 2 66 8 2
319 96 167278 3 91 6 3
350 172 58163 2 81 7 1
373 63 113359 2 62 8 3
418 171 4760 2    34* 10 2
432 4.5 104010 2 84 4 2
444 285 13259 3 59 10 5
448 135.5 229757 2 69 9 2
452 107 201675 1 100 5 2
Average - 176 130637 2.11 2.47 - 2.47
15 278 57329 2 72 12 1
17 11.5 40557 1 100 5 1
41 64 202454 1 100 5 2
69 221 33961 2 74 10 1
97 11 129752 1 100 8 1
99 274.5 8923 1 100 7 1
122 157 81706 2 100 7 3
279 645 76580 1 53 6 1
284 293 9041 1 100 10 1
363 65.5 23549 3 100 6 2
X4 only
(n = 10)
411 160 70674 2 46 11 1
Average - 198 66775 1.50 - 2.2
a Position Specific Scoring Matrices phenotype (109)
b At time of env amplification
c Heteroduplex Tracking Assay V3 variants
d Single Genome Amplicfication V3 variants
*All V3 variant sequences were not obtained
3.4.3 SINGLE GENOME AMPLIFICATION OF SUBJECT ENVS
To better understand coreceptor evolution, we specifically generated env amplicons
from subject plasma, including subjects harboring multiple V3 variants in vivo.  These
chronically infected subjects were assumed to harbor both R5- and X4-tropic variants (as
predicted by PSSM) that were able to coexist in vivo, presenting an opportunity to detect the
changes occurring during coreceptor switching.  The recent advent of HIV-1 single genome
amplification (SGA) (114, 161), provides a method to generate large numbers of env gene
amplicons by limiting dilution PCR, eliminating recombination and/or resampling that occurs
during the bulk PCR amplification process (65, 137).  Although coreceptor usage can be
mapped at least in part to small changes in the V3 region, we used SGA to generate full-
74
length gp160 env amplicons (55, 114, 161) and understand any coreceptor phenotype-
associated changes that may be occurring throughout env.
For each of the 46 subjects, between 4 and 22 full-length env amplicons were
generated, each env was sequenced and DNA chromatograms were screened for the presence
of multiple peaks (indicating multiple templates), premature stop codons (indicating non-
functional envs) from V1 to the end of gp120, resulting in a total of 412 in-frame envs (Table
3.2).  The env amplicons are each numbered according to subject number and amplicon
number (x.y), where x represents the subject number and y represents the specific amplicon
number (the amplicon numbers are not consecutive).  We first aligned all 412 envs using
ClustalW, and as expected, intra-subject envs aligned together, and inter-subject branches
were more dispersed, an example of 4 patients is shown in Fig. 3.2A.  Next, V3 sequences
from env amplicons were used to generate PSSM coreceptor predictions (Table 3.2).
Here we found that compared to the previous HTA analysis there was a high
concordance between the two assays; of the 41 subjects with V3 sequences generated by both
HTA and SGA, many were the same (24/42 subjects, 57%), however there were some V3
sequences generated by SGA that were not generated by HTA (17/42 subjects, 40%).  The
higher number of V3 variants by SGA (compared to SGA) reflects the capacity of SGA to
detect rare V3 variants that do not form a visible band in the HTA, or were not separated in
the HTA.
75
Fig. 3.2.  ClustalW alignment of envs generated by single genome analysis.  (A).  Maximum-liklihood trees
based on V1-end of gp120 sequences are shown for subjects 15, 39, 99 and 170.
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Fig. 3.2.  ClustalW alignment of envs generated by single genome analysis.  (B).  Maximum-liklihood trees
based on V1-end of gp120 sequences after eliminating V3 sequence are shown for subjects 15, 39, 99 and 170.
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3.4.4 CONCORDANCE OF ENV GENOTYPE AND PHENOTYPE BY PHYLOGENETICS
The full-length env amplicon sequences were used to determine correlation between
the PSSM coreceptor prediction and the branching of the subject env amplicons (Fig. 3.2A).
The highlighted sequences represent those amplicons with a V3 variant that is considered to
encode an X4-tropic Env protein by PSSM, suggesting an obvious outgrowth of a distinct
env lineage that is X4-tropic.  Intrasubject env branching was particularly strong; for subjects
that contained both R5- and X4-tropic envs (by PSSM), 100% branched with high bootstrap
values, (>99% in 15/19 subjects).  Using the SGA-generated V3 sequences, we compared the
overall number of identical V3 variants associated with each group.  The average number of
V3 variants associated with the R5-monotropic group was significantly different compared to
the mixed group (p <0.03, two-tailed t-test), and was also significantly different when
comparing the X4-monotropic group to the mixed group (p <0.01).  Again there was no
significant difference when comparing the R5- to X4-monotropic group.
Based upon PSSM coreceptor predictions, the distinct phylogenetic branch points
between R5- and X4-tropic envs suggests two scenarios in which X4-tropic env genes arise
(assuming in both cases the branch point(s) occurred at a much earlier time point): either an
X4-tropic variant is generated that rapidly acquires other env mutations to establish itself in
vivo (and in doing so generates its own distinct lineage), or HIV-1 in vivo produces divergent
R5-tropic populations, of which one or more is permissive to mutations that allow X4-
tropism (and indicates not all env variants are susceptible to X4-tropism).  In either scenario,
the coreceptor prediction correlates to phylogenetic clustering of env, even though PSSM-
based coreceptor prediction is based on V3 (8-10% of the sequences used for phlyogenetic
analysis).  Phylogenetic trees were reconstructed after eliminating V3 from env sequences
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and branching occurred in the same manner (Fig. 3.2B), suggesting that coreceptor switching
sequence motifs are not limited to V3, and the backbone env sequence is an integral
component of coreceptor evolution to X4-tropism, although where and when the backbone
sequence changes occur also remain unclear.  Alternatively, the X4 and R5 viruses could be
compartmentalized in different cell types that would limit recombination and enhance the
phylogenetic differences based on a founder effect.
3.4.5 PHENOTYPING USING ENV AMPLICONS
To test the coreceptor phenotype of each env amplicon, an overlapping PCR
technique was used to “stitch” a CMV promoter to the env amplicon (adapted from Kircherr
et al. (114)), producing a linear env expression amplicon that was directly used for
transfection.  The elimination of the cloning involved in traditional phenotyping assays was
both time- and cost-effective.  The linear CMV promoter-stitched env amplicons were
cotransfected with a ∆env HIV-1 backbone containing a luciferase gene (Luc3) to generate
single cycle pseudovirions.  Equal volumes of virus were used to infect MAGI cells
expressing either CCR5 or CXCR4.  HIV-1 clones JR-FL, NL4-3 and 89.6 were used to
generate env amplicons with the CMV promoter added as examples of R5-, X4- and dual-
tropic Env entry phenotypes, respectively.  The fold-activation over background is shown for
Envs from subjects 15, 39, 99 and 170 (Table 3.3).  Envs were scored as functional if the
luciferase signal was at least 10-fold over background in CCR5 expressing cells and at least
5-fold over background in CXCR4 expressing cells.  In the case where Env was functional in
both cell types, a ratio of CCR5:CXCR4 signal over background was calculated.  The ratio
was used as a further indicator of Env coreceptor phenotype: a ratio ≤ 0.4 was considered
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X4-tropic, a ratio between 0.4 and 10 was considered dual-tropic, and a ratio ≥ 10 was
considered R5-tropic.
Overall, 175 Env amplicons were R5-tropic (43%), 66 Envs were X4-tropic (16%),
74 Envs were dual-tropic (18%) and 96 Envs were functionally dead after two independent
CMV promoter-stitch PCR’s (PCR products were generated, but no infectious pseudovirus
was produced) (23%).  Subjects 70, 284, 373 and 432 did not produce any functional Envs
(little or no infection), and of the remaining subjects, twelve were R5-tropic only, sixteen
were R5- and dual-tropic, six were mixed (R5-, X4- and dual-tropic variants), two were X4-
and dual tropic, and six were X4-tropic only.  Some of these groups did contain functionally
dead viruses, as expected, but there was no correlation between the groups and percentage of
dead virus, as opposed to previous studies (164).
The average viral load for each group ranged between 66,775 and 130,637 RNA
copies/ml, with slightly higher virus numbers in the X4- and dual-tropic and X4-tropic only
groups (Table 3.2).  The X4- and dual-tropic group was anomalous in that it had a
significantly higher mean viral load compared to the other groups, most likely because this
group contained only two subjects.  The mean CD4 count varied among the subjects, but the
X4- and dual-tropic group had lower average CD4 counts than the other groups.  The data
suggest that phenotypically different in vivo populations can co-exist and there is most likely
an interplay between env variants, allowing for those with a selective advantage to endure.
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TABLE 3.3.  Subject Env phenotypes
Patient and
phenotype
group
Env
amplicon
CCR5
(fold
above
bkgd)
CXCR4
(fold
above
bkgd)
R5 to X4
ratio
Functional
phenotype
PSSM
phenotype Correlation
15.01 150.54 4.80 - CCR5 CXCR4 FALSE
15.04 32.87 10.12 3.25 DUAL CXCR4 TRUE
15.05 78.66 3.07 - CCR5 CXCR4 FALSE
15.06 52.64 9.14 5.76 DUAL CXCR4 TRUE
15.07 85.30 8.43 10.12 CCR5 CXCR4 FALSE
15.08 0.05 0.08 - DEAD CXCR4 -
15.09 10.68 0.43 - CCR5 CXCR4 FALSE
15.12 14.77 0.14 - CCR5 CXCR4 FALSE
15.14 19.58 0.13 - CCR5 CXCR4 FALSE
15.15 2.73 0.69 - DEAD CXCR4 -
15.16 6.96 0.34 - DEAD CXCR4 -
Patient 15 - R5
and dual
15.17 8.56 0.12 - DEAD CXCR4 -
39.01 372.62 14.66 25.42 CCR5 CXCR4 FALSE
39.02 161.94 12.80 12.65 CCR5 CXCR4 FALSE
39.04 286.77 11.10 25.84 CCR5 CXCR4 FALSE
39.05 244.34 2.78 - CCR5 CCR5 TRUE
39.06 166.29 1.92 - CCR5 CXCR4 FALSE
39.07 27.37 1.03 - CCR5 CCR5 TRUE
39.09 12.31 11.66 1.06 DUAL CXCR4 TRUE
39.10 18.35 53.31 0.34 CXCR4 CCR5 FALSE
39.14 20.68 11.62 1.78 DUAL CXCR4 TRUE
Patient 39 –
mixed
39.16 49.38 6.07 8.13 DUAL CXCR4 TRUE
99.01 22.63 3.20 - CCR5 CXCR4 FALSE
99.03 7.75 3.75 - DEAD CXCR4 -
99.04 13.39 2.70 - CCR5 CXCR4 FALSE
99.05 24.21 0.35 - CCR5 CXCR4 FALSE
99.06 19.23 0.56 - CCR5 CXCR4 FALSE
99.07 19.17 1.91 - CCR5 CXCR4 FALSE
Patient 99 –
R5 only
99.08 18.35 1.09 - CCR5 CXCR4 FALSE
170.01 87.82 26.49 3.32 DUAL CCR5 FALSE
170.04 4.26 1.32 - DEAD CCR5 FALSE
170.10 49.67 1.47 - CCR5 CCR5 TRUE
170.11 6.04 8.31 0.73 DUAL CCR5 FALSE
170.12 32.19 7.27 4.43 DUAL CXCR4 TRUE
170.13 79.24 495.23 - CXCR4 CCR5 FALSE
170.16 23.49 7.05 3.33 DUAL CCR5 TRUE
170.17 61.24 32.76 1.87 DUAL CXCR4 TRUE
170.02new 39.20 1.45 - CCR5 CCR5 TRUE
170.04new 46.07 77.51 0.59 DUAL CCR5 FALSE
170.05new 13.65 6.61 2.06 DUAL CXCR4 TRUE
170.07new 37.65 2.26 - CCR5 CXCR4 FALSE
170.09new 14.24 3.99 - CCR5 CCR5 TRUE
170.10new 11.09 11.35 0.98 DUAL CXCR4 TRUE
Patient 170 –
mixed
170.11new 9.44 3.01 - DEAD CCR5 FALSE
JR-FL 15.57 0.75 - CCR5 CCR5 TRUE
NL4-3 2.99 38.33 - CXCR4 CXCR4 TRUEControls
89.6 17.33 25.07 0.69 DUAL CXCR4 TRUE
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3.4.6 PSSM POSITIVELY PREDICTS ENTRY PHENOTYPE
Comparison of the PSSM coreceptor predictions to the entry phenotype (disregarding
the non-functional Envs) reveals that 55% of Envs were predicted correctly by PSSM.  The
Envs with inconsistent PSSM predictions and entry phenotype were subject to sequence
analysis.  For those Envs that were R5-tropic by function, but X4-tropic by PSSM prediction,
most V3 sequences contain an Arg or Lys at position 11 and/or 25.  This inconsistency can
be attributed to the inclusion of the 11/25 rule in PSSM, however, basic amino acid changes
at these position are indicative, but not definitive, predictors of X4-tropism, representing a
limitation of PSSM.  Nine out of these 58 (16%) Envs did exhibit use of CXCR4 > 5-fold
above background, but the R5 to X4 ratio was ≥ 10 and was recorded as R5-tropic.  Overall,
the average fold activation for these Envs was 3.27 (range = 0.01-14.66) suggesting that there
was basal X4-usage, which was reflected as a discrepancy between the PSSM prediction and
phenotype.
For Envs that were X4-tropic by function, but predicted to be R5-tropic by PSSM
prediction, the V3 sequences contained insertions and/or deletions and many other non-
consensus amino acids throughout V3.  Five of the six subjects that were predicted to harbor
mixed populations by PSSM were indeed mixed by phenotype.  Only subject 449 (predicted
to be R5 only by genotype and mixed by phenotype) did not correlate, but for this subject
only one (non-canonical) V3 sequence was generated, explaining the inability of PSSM to
correctly predict phenotype.  This suggests that the PSSM coreceptor prediction tool is a
good preliminary approach to screen Env, but a phenotype assay still reveal inconsistencies
showing the gap remaining between these two approaches.
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3.4.7 ENV VARIANTS WITHIN EACH PHENOTYPIC GROUP
The phenotype assay provides a reliable phenotypic test for the env amplicons
generated from subject samples, allowing the detection of mixed env variants in vivo.
Importantly, the phenotype test definitively proves the existence of dual-tropic envs in vivo,
which are presumed to be the precursor for coreceptor switching to X4-monotropic envs.
The dual-tropic Envs are more likely to be predicted as being X4-tropic by PSSM compared
to the X4-tropic Envs, but there is no evidence that dual-tropic Envs have fewer X4-tropic
signature sequences than the X4-tropic variants themselves, making differentiation between
X4- and dual-tropic Envs difficult without a phenotypic test.  Even within a subject, there
may be multiple envs backbones (as indicated by the intra-subject branching in the
phylogenetic analysis), but even within a lineage, envs are not completely homogenous and
contain many substitutions throughout (as indicated by the minimal env amplicons that were
identical).
The coreceptor phenotype-genotype analysis reveals that the association between V3
genotype and coreceptor phenotype is strong, and other mutations in env are also associated
with coreceptor switching, although they are not as strongly associated.  The drawback of the
PSSM genotype prediction tool is the uncertainty of the classification of dual-tropic variants,
which are likely to be predicted as X4-tropic if there is the presence of any X4-like signature
sequence, and R5-tropic if there is the absence of such sequences.  The phenotype assay used
here is able to measure R5-monotropism, dual-tropism and X4-monotropism in a single
subject, demonstrating the coexistence of multiple Env variants in chronically infected HIV-1
subjects.
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3.5 DISCUSSION
The necessity of HIV-1 to evolve and undergo coreceptor switching remains unclear,
although the acquisition of X4-tropism expands the target host range to include naïve T cells
expressing CXCR4 (19, 89, 132, 220).  However, the disadvantages to coreceptor switching
are much more obvious; the low transmissibility of X4-tropic virus (166), and the low fitness
of virus variants that have acquired coreceptor switching-associated mutations (166, 204).
The delay in X4-tropism and the low incidence of coreceptor switching in some subtypes (1,
9, 16, 17, 31, 169, 217) indicates alternative options; either X4-tropism represents the end of
the evolutionary lineage, when all other potential pathways have been exhausted or that  X4-
tropic variants can survive in naive cells until the subject is immunodeficient such that the
slow growing X4-tropic variants are able to replicate efficiently.
Multiple V3 variants.  Using the V3 sequences generated by both V3-HTA and env
SGA, we observed reduced numbers of V3 variants in an R5- or X4-monotropic subject
compared to subjects that harbored both variants.  This establishes that an increase in the
number of V3 variants is an indication of a coreceptor switching virus population in vivo.  At
the R5-monotropic stage of infection there is a small number of V3 variants, and in order to
expand host tropism a new V3 population is generated that has an broadened coreceptor
range, followed by the outgrowth of the high fitness V3 population once a X4-monotropic
population has been established.  Previous studies have used the V3-HTA, HMA or
population-based sequencing methods to detect V3 variants (51, 52, 156), which all rely on
sequencing of cloned products to identify V3 genotypes present in a population.  The direct
sequencing of V3-HTA bands takes advantage of the V3-HTA to resolve phenotypic
mixtures and allows the rapid acquisition of the individual sequences.
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Genotype and Phenotype correlations.  The use of PSSM to predict entry
phenotype of the env amplicons in this study largely correlated with the measured entry
phenotype, although ~20% of the Env proteins were found to use a different coreceptor.  The
PSSM scores are useful in primary analysis of subject populations in vivo, however, the
functional test demonstrates the discordance between the two; the pitfall of PSSM and many
other prediction tools is the inclusion of the 11/25 rule and the net charge rule, which are not
absolute in terms of the requirement for coreceptor switching.  In this study, the 20% of Envs
that were non-functional in our assay could represent variants that use coreceptor at low
levels that do not register on our assay, or that these Envs use an alternate coreceptor that we
have not tested.  The practical implication of this study for coreceptor phenotype prediction
tools is that they are useful for coreceptor phentoype prediction overall, but they cannot
predict dual-tropism nor the capacity to which Envs are able to use each coreceptor in vivo.
in vivo evolution and coexistence.  Recent studies have suggested the pathway to
coreceptor switching requires the successive acquisition of mutations (115, 164, 165).
Additionally, minimal mutations are generated during coreceptor switching in vitro (166),
whereas coreceptor switching in subjects is associated with env mutations that are more
remarkable (200, 220).  Generally, mutations within V3 produces low fitness viral variants,
whereas a combination of mutations throughout env (including V3) is more likely to generate
infectious virus capable of X4-usage with a high fitness.  The low fitness of evolutionary
intermediates is associated with low-abundance variants that have reduced virus-coreceptor
affinities (172, 175).  For subjects who have measurable mixtures of X4-tropic and dual-
tropic variants, extended use of a CXCR4 inhibitor shifted X4-tropic virus back to using
CCR5 (64), with accompanying mutations in V2 and V3.  Consistently, the accidental
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administering of a CCR5 inhibitor to a subject harboring X4-tropic virus showed reversion to
predominantly CCR5 using virus after therapy cessation (228), suggesting selective pressures
(supplied by the immune system or anti-HIV therapies) encourage the replication of virus
with the most efficient coreceptor usage, rather than an absolute shift towards X4-tropism
(64, 228).  The detection of the minor variants that arise during coreceptor switching is likely
to represent a rich pool of virus that can reliably determine the pathway of coreceptor
switching – do mutations associated with coreceptor switch selectively arise in V3, or are
they generated throughout env?  The low fitness of newly generated X4-tropic variants will
sometimes be out competed by the already established R5-tropic variants, and the R5-tropic
variants that are acquiring the ability to use CXCR4 will relinquish some interaction with
CCR5, making these functional intermediates difficult to interpret, but sequence analysis
may provide further clues.  For this type of analysis, detection of small virus populations will
be required.  Limits of viral variant detection has always been a concern, however, the limit
of detection in our current study was as low as 2% of the population using SGA, and 10%
using the V3-HTA, as opposed to the 20-30% detection limit for standard genotyping (130,
133, 162, 219).
We propose the final shift to X4-tropism results after the acquisition of enough
compensatory mutations for the original low fitness variants that are generated.  Further
mutations in the X4-tropic virus will allow that particular env to interact with CXCR4
efficiently and establish a new lineage.  We cannot discount the possibility that in vivo
recombination of viral variants is another potential pathway to coreceptor switching (145),
but these pathways are not mutually exclusive.
CHAPTER FOUR
SINGLE MUTATION BETWEEN THE EPITOPES OF HIV-1 NEUTRALIZING
ANTIBODIES 2F5 AND 4E10 CONFERS INCREASED NEUTRALIZATION
SENSITIVITY TO BOTH ANTIBODIES
Milloni Patel and Nobutoki Takamune contributed equally to this work, the data is currently
being used to prepare a manuscript for peer-reviewed publication.
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4.1 SUMMARY
The membrane proximal external region (MPER) is located in the gp41 subunit of the
HIV-1 Env protein, in close proximity to the viral membrane.  The MPER contains the
epitopes of highly neutralizing antibodies 2F5 and 4E10, making the MPER an attractive
target for generation of anti-HIV-1 antibodies as part of a comprehensive vaccine.  Here, we
demonstrate that one mutation in the MPER (amino acid 668) located between the epitopes
of 2F5 and 4E10 is able to dramatically change the neutralization sensitivity of multiple
Envs.  A mutation from the consensus Ser to Gly at position 668 increases the neutralization
sensitivity of Env ten-fold for 2F5 and is up to 3-fold for 4E10.  The effect of the mutation is
contained to the MPER, and there is no apparent effect on expression, folding, infection or
the global structure (as indicated by no change in neutralization by 2G12 or inhibition by T-
20 or TAK-779).  We propose that Gly 668 is an ideal mutation to include as part of an Env-
containing vaccine with minimal disruption to Env, except to expose the MPER for
generation of strongly neutralizing MPER directed antibodies.
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4.2  INTRODUCTION
Human Immunodeficiency Virus Type 1 (HIV-1) infection rarely elicits broadly
reactive, neutralizing antibodies.  Of the few neutralizing antibodies that have been
characterized, all of them bind to the Env protein.  Four antibodies bind to the gp120 subunit:
IgGb12 (CD4 binding site epitope) (24), 17b (CD4-induced epitope) (211), 447-52D (V3
epitope) (83), and 2G12 (glycans on the surface of Env) (216).  Three broadly neutralizing
antibodies are gp41-directed: 2F5, 4E10, and Z13 (153, 208, 247), which are all targeted to
the membrane proximal external region (MPER) of gp41, adjacent to the viral membrane.
Previous studies indicate that these MPER-directed antibodies are the most potently
neutralizing anti-HIV-1 monoclonal antibodies (14) and require elements of the viral
membrane to bind (2, 96, 194).
The epitopes of 2F5 and 4E10 have been studied in considerable detail, and crystal
structures confirm the 2F5 epitope (ELDKWA) is present at amino acids 662-667 and the
4E10 epitope (NWFDIT) is present at amino acids 671-676 (HXB2 numbering) (26, 160).
Binley et al. showed that these two antibodies are the most cross-neutralizing in a study that
included many well characterized neutralizing antibodies (14). The 2F5 antibody can
neutralize 67% of isolates from a wide cross-subtype panel of Envs at a low concentration,
whereas 4E10 is able to neutralize 100% of isolates from the same panel with an even
potency at a relatively higher concentration (14).  Other studies also suggests that 2F5 and
4E10 are amongst the most potent neutralizing antibody capable of neutralizing newly
transmitted HIV-1 variants (143, 177) , although they lose potency when used to neutralize
Envs from chronic subjects and long-term non-progressors (20, 191).  Even with this caveat,
only a handful of escape mutations have been reported for 2F5 and 4E10 (140, 246).  Alanine
89
scanning mutations have revealed that resistance can occur against 2F5 with mutations at
D664, K665, and W666, and against 4E10 with mutations at W672, F673, and W680.
Neutralization escape in vivo to 2F5 has been found at D664 and K665; however no
neutralization escape has been reported for 4E10 (246).  The high potency of these antibodies
is most likely due to the location of their linear epitopes in a highly conserved region of Env,
which is presumably required for envelope-mediated fusion (56, 57, 151, 193).  More
recently the epitope of a variant of antibody Z13, Fab Z13e1, has been mapped to be between
and overlapping with the epitopes of 2F5 and 4E10 (encompassing HXB2 666-677),
suggesting this short region is unique in its ability to generate highly neutralizing antibodies.
Therefore, the MPER is less likely to evolve mutations compared to other regions on Env,
making the MPER a natural target for HIV-1 vaccine development.
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4.3 MATERIALS AND METHODS
4.3.1 ENV AMPLIFICATION FROM SUBJECT SAMPLES
Subject virus was extracted and amplified from human plasma as previously
described (156) using primers described in Derdeyn et al. (55).  Subject envs were cloned
into pcDNA3.1/V5/His expression vectors (Invitrogen).
4.3.2 PLASMIDS, MONOCLONAL ANTIBODIES, AND INHIBITORS
All monoclonal antibodies were obtained through the NIH ARRRP: 2F5 (Cat. No.
1475), 4E10 (Cat No. 10091), and 2G12 (Cat. No. 1476).  T-20 (Cat. No 9845) and TAK-779
(Cat. No. 4983) stocks were also obtained through ARRRP.  Molecular clone of JR-FL
gp160 (Genbank accession U63632) in the plasmid pSV was kindly provided by Dr.
Nathaniel Landau (54).  JR-FL isolates has been shown to use the CCR5 coreceptor (R5-
tropic) and fail to form syncytia in MT-2 cell culture (54).
4.3.3 EXPRESSION OF WILD TYPE AND MUTANT PSEUDOTYPES  
env genes containing modifications in MPER were generated by introducing
mutations using QuikChange site-directed mutagenesis (Stratagene).  To generate
pseudotyped luciferase reporter viruses capable of a single cycle of replication, we used the
pNL4-3.Luc.R-E- (Luc3) plasmid, obtained from the NIH ARRRP (Cat. No. 3418).  The
Luc3 plasmid contains a frameshift within the env gene and has a firefly luciferase gene in
place of the nef gene.  We cotransfected plasmids expressing the HIV-1 gp160 with Luc3
after mixing with Fugene 6 transfection reagent (Roche Applied Science), using 293T cells to
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generate viral stocks.  Supernatants were collected and used to infect TZM-βl or MAGI-
CCR5 expressing cells (NIH ARRRP, Cat. No 8129 and 3522, respectively).
4.3.4 INFECTION AND NEUTRALIZATION ASSAYS  
Pseudotyped single-cycle reporter virus (100 µl) was mixed with 100 µl CCR5-
MAGI or TZM-βl cells at 5 x 105/ml for 48 h at 37°C in a 48-well plate.  To confirm
luciferase readings were in the linear range, extra wells were infected with dilutions of the
virus.  Cells were washed with 200 µl 1X PBS, then lysed with 100 µl 1X lysis buffer
(Promega).  A 50 µl aliquot of lysate was used to measure luciferase activity using the
FluorStar luminometer and analyzed with the Fluorstar software (BMG LABTECH).  To
measure neutralization sensitivity, 50 µl of virus was pre-incubated with 50 µl of antibody or
inhibitor for 1 h at 37°C in a 48-well plate (for TAK-779, 50 µl of TAK-779 was incubated
with cells for 1 h at 37°C in a 48-well plate prior to the addition of virus).  The starting
concentration of antibody and inhibitors used for assays was: 2F5 @ 5.0 µg/ml, 4E10 @ 5.0
µg/ml, 2G12 @ 5.0 µg/ml, T-20 @ 0.5 µM, and TAK-779 @ 10.0 µM.
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4.4 RESULTS
4.4.1 INFECTIVITY AND NEUTRALIZATION OF SUBJECT ENVS
Two Envs each from six HIV-1 positive individuals infected with subtype B were
PCR amplified using primers that include the open reading frames of gp120 and gp41 and
cloned into the pcDNA3.1/V5/His expression vector.  Each Env clone is identified by subject
name followed by the clone number.  The Env clones, along with a subtype B reference
strain JR-FL, were pseudotyped and tested, all 12 Envs were functional (data not shown).
All the Envs were subsequently tested for neutralization against 2F5, 4E10 and polyclonal
sera HIV-Ig (Fig. 4.1).  The HIV-Ig was able to neutralize all the Envs to some extent (IC50
= 8.2 µg/ml to > 50 µg/ml) (Fig. 4.1 G-I).  We also found that the Envs exhibited a range of
neutralization sensitivities to 2F5 and 4E10 (Fig. 4.1 A-F).  In agreement with previous
literature, more Envs showed some neutralization susceptibility to 4E10 (n=8) compared to
2F5 (n= 6) at 10.0 µg/ml.  This suggested a wide range neutralization susceptibility of
subjects Envs to monoclonal antibodies.
4.4.2 U NIQUE S UBJECT E NV SEQUENCE CORRELATES WITH NEUTRALIZATION
SENSITIVITY
The range of neutralization sensitivities suggested a sequence specific susceptibility,
so all Env clones were sequenced to determine if the 2F5 and 4E10 epitopes were present and
also to assess the impact of the surrounding amino acid sequence (Fig. 4.2).  For the 2F5
epitope, 8/12 Envs (including JR-FL) contained the ELDKWA consensus epitope, and of
these, 6 Envs were susceptible to 2F5 neutralization (Fig. 4.1).  Env 1405.47 contained the
consensus epitope sequence and was the most susceptible to 2F5 neutralization with an IC50
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= 1.6 µg/ml (the only Env with an IC50 less than 10.0 µg/ml).  The remaining four Envs
contained a ELDQWA or ALDKWA epitope sequence and were resistant to neutralization.
All Envs were also analyzed for the presence of the 4E10 epitope (Fig. 4.2).  Four Envs
(from two subjects) did not contain the NWFDIT consensus epitope and were neutralized 20-
40% at 10µg/ml.  The remaining 8 Envs contained the NWFDIT consensus epitope and were
susceptible to various levels of 4E10 neutralization: four were not neutralized (JR-FL,
Z02.41, 1219.06, 1219.51), two had intermediate levels of neutralization (35-45% at 10.0
µg/ml; 2275.42, 2275.71) and two Envs, 1405.47 and 1405.56 were the most sensitive to
4E10 neutralization (IC50 = 0.6 and 6.8 µg/ml, respectively).
Fig. 4.1.  Infectivity of Envs in the presence of (A-C) 2F5, (D-F) 4E10 or (G-I) HIV-Ig.  Four Envs are shown
in each graph for the purpose of clarity.
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Fig. 4.2.  Sequence alignment of MPER region from Env isolates.  Underlined sequence indicates epitopes of
antibodies 2F5 and 4E10.  IC50 values are also provided for these antibodies.
The 1405.47 Env was of particular interest due to its high sensitivity to both 2F5 and
4E10.  Upon further sequence analysis, we noted that it contained the consensus epitopes for
both antibodies, but was the only Env that had a G668 present in the 3 amino acid sequence
between the 2F5 and 4E10 epitopes, whereas the remaining 11 Envs contained a Ser or Asn
at this position.  Analysis of other Env variants from the LANL database of gp41 sequences
suggests the high conservation of amino acid 668 in the MPER, as are most other positions
within the MPER.  This suggested the presence of G668 was responsible for the high
sensitivity to MPER antibody neutralization.
4.4.3 EFFECT OF G688 MUTATION ON MPER
Upon further screening, a second env from subject 1405 (clone 55) also encoded
G668.  Both env 1405.47 and 1405.55 were subjected to site-directed mutagenesis to
generate the consensus S668 sequence.  Conversely, Env 1405.56, from this same subject but
already encoding S668, was also subjected to site-directed mutagenesis to generate the G668
sequence.  These three mutated env genes and their parents were tested for sensitivity to 2F5
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and 4E10 neutralization in the pseudotype assay (Fig. 4.3).  The parent 1405.47 Env protein
(with a naturally occurring G668, IC50 = 1.6 µg/ml) had reduced sensitivity to 2F5 by at least
five-fold in the presence of S668 (IC50 > 5.0 µg/ml) (Fig. 4.3A).  Similarly, the parent Env
1405.55 was at least five times more sensitive to 2F5 (IC50 = 1.0 µg/ml), compared to the
mutant Env with S668 (100% infectious at 5.0 µg/ml) (Fig. 4.3B).  Conversely, the parental
Env 1405.56 (with S668) was at least five times more sensitive to neutralization when
mutated to G668 (IC50 = 1.0 µg/ml), although neutralization was incomplete (Fig. 4.3C).
This suggests the presence of G668, which lies outside of the 2F5 epitope, changes the local
MPER structure such that 2F5 can bind more efficiently.
The mutated Envs were also tested for neutralization by 4E10 (Fig. 4.3D-F).  Overall
the same effect was seen for 4E10 sensitivity except that the magnitude of the effect was
smaller and, as with 2F5, the S668G substitution in 1405.56 had a smaller effect in creating
antibody sensitivity.
Finally, we assayed subject 1405 plasma for the presence of antibodies that compete
with 2F5, or that bind to MPER peptides.  There were no detectable antibodies that competed
with 2F5 for binding Env or bound to MPER peptides suggesting that subject 1405 did not
contain any MPER-directed antibodies, explaining the presence of G668 in vivo.
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Fig. 4.3.  Infectivity of Envs (+/- G668S or S668G) in the presence of  (A-C) 2F5, or (D-F) 4E10.
4.4.4 EFFECT OF G688 ON JR-FL ENV
To extend this observation from the subject sample, we used the prototypic CCR5-
tropic Env JR-FL.   Two JR-FL S668G clones were generated and tested for neutralization
sensitivity to 2F5, 4E10, monoclonal antibody 2G12 (a neutralizing antibody directed to the
glycans on the surface of Env), CCR5 inhibitor TAK-779, and fusion inhibitor T-20 (Fuzeon)
(Fig. 4.4).  For JR-FL S668G, we confirmed an increased sensitivity to 2F5 neutralization,
the IC50 was reduced 10-fold from 2.9 µg/ml in JR-FL wild type to 0.1-0.3 µg/ml in JR-FL
S668G mutants (Fig. 4.4A).  We also observed an increase in neutralization sensitivity to
4E10, decreasing the IC50 more than 3-fold from 0.36 µg/ml in JR-FL wild type to 0.1 µg/ml
in JR-FL S668G (Fig. 4.4B).  Again the effect was not as pronounced for 4E10 compared to
2F5, as seen with patient Envs.  We observed no obvious difference comparing the
neutralization/inhibition of JR-FL wild type and JR-FL S668G by 2G12, TAK-779 and T-20
(Fig. 4.4C-E).  The analysis of the JR-FL wild type and JR-FL S668G env genes confirms
the observations made with subject 1405 env genes that G668 increases sensitivity to
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neutralization by MPER antibodies 2F5 and 4E10.  However, the global structure of the Env
protein (both gp120 and gp41) and the interaction with coreceptor remains unchanged as
evidenced by the similar sensitivity of JR-FL wild type and JR-FL S668G Envs to 2G12, T-
20 and TAK-779.
Fig. 4.4.  Infectivity of JR-FL and JR-FL G668 mutants in the presence of  (A) 2F5, (B) 4E10, (C) HIV-Ig, (D)
TAK-779, or (E) T-20.
The JR-FL wild type and JR-FL G688 Envs confirm the observations made in the
subject Envs that the presence of G688 increases sensitivity to neutralization by MPER
antibodies 2F5 and 4E10.  However, the global structure of Env (both gp120 and gp41) and
the interaction with coreceptor remains unchanged as evidenced by the similar sensitivity of
JR-FL wild type and G688 Envs to 2G12, T-20 and TAK-779.
4.5 DISCUSSION
In summary, we have isolated an env gene that contains a non-consensus Gly at
amino acid 668, making virus displaying the encoded Env protein highly sensitive to
neutralization by both 2F5 and 4E10.  This substitution was found in nine out of ten clones
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from a single subject suggesting it was not the result of PCR error during amplification,
although we cannot definitively rule out this possibility.  The phenotype was reproduced in
the prototypic JR-FL Env protein, indicating that the effect was not specific to a single Env
backbone.  We do not believe this substitution causes a global effect on Env protein structure
or function as we found no change in sensitivity to inhibitors that target several other Env
protein functions or conformations.  A mutation at position 668 (to Asn) has previously been
reported to increase sensitivity to 4E10, although in contrast to the Gly substitution described
here, the Asn substitution decreased sensitivity to 2F5 (246).
Finally, there are two explanations for the effect of this substitution.  First, it is
possible that position 668 interacts directly with these two MPER antibodies.  The second
possibility is that position 668 controls the conformation or accessibility to the MPER.  In
this scenario it may be that the inherent flexibility of a position with Gly exposes the MPER
in a way that the consensus Ser does not.  An important consequence of this possibility is that
an Env immunogen might similarly expose the MPER and as a consequence more readily
induce the production of host antibodies to this region.  While this is a potentially useful
concept in the design of an immunogen for the production of antibodies, it will also be
necessary to design a vaccination strategy that is able to present the Env protein in a way that
recapitulates these subtle differences in Env conformation.
CHAPTER FIVE
CONCLUDING REMARKS
5.1 OVERVIEW   
The V3 region of env has been extensively studied since the discoveries of the HIV-1
coreceptors, chemokine receptors CCR5 and CXCR4.  Recent advances in the
characterization of Env have included crystal structure elucidation of the core gp120
(revealing a protruding V3 region after CD4 binding) and multiple structures of V3 peptides
bound to antibodies, all contributing to the understanding of the functional role of V3.  The
crown of V3 makes contact with the extra-cellular loop 2 of the chemokine receptors,
whereas the base of V3, along with the bridging sheet of gp120, contact the N terminus of the
coreceptor.  More complicated to interpret have been the anomalies associated with
coreceptor switching, namely the convoluted evolutionary pathway to coreceptor switching,
and the limited appearance of it in some HIV-1 subtypes.
In Chapter 2, we have determined that differences in the biological properties
concerning coreceptor usage of subtype B and subtype C Env are rooted in V3-based
structure.  The questions we wanted to answer with this project were: (1) what sequence
differences exist in the V3 region of subtype B and subtype C; (2) how do sequence
differences in the V3 region of subtype B and subtype C affect structure; and (3) how can
these results be interpreted to understand evolution of coreceptor usage.  Our studies indicate
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that the V3 region stem region (positions 9-24) is where the differences exist.  This region is
more capable of accepting structural changes than the base region (positions 1-8 and 25-35),
and contains the crown region that binds to the ECL2 of the coreceptor.  V3 mAb binding
suggests that the epitope for these antibodies is also located in the 9-24 region, and more
fundamentally, the consensus V3 sequence differences between subtypes B and C also fall
into the 9-24 region.  Together these data suggest that the V3 structure differs in the 9-24
region between subtype B and subtype C, potentially providing the biological basis for the
limited cross-subtype neutralization by V3 mAbs and evolutionary constraints in coreceptor
usage between subtypes B and C.
Chapter 3 furthers the coreceptor switching story by beginning to assess the in vivo
evolutionary changes to env in HIV-1 subjects who are experiencing a coreceptor switch.
We have used the subject samples to understand coreceptor switching; env genes were
sequenced, qualitatively assessed for coreceptor usage and analyzed for genotype-phenotype
linkages to understand the mechanisms of coreceptor switch in vivo.  The study would not
have been possible without the amplification of 406 subject env genes from 46 subjects, the
largest data set of its kind linking phenotype to full-length env genotype.
From these studies we conclude that the coreceptor switch begins by random accrual
of mutations within env, some are fortuitous in that they change the ability of V3 to interact
with a coreceptor.  These preliminary mutants still have a dampened ability to use CCR5, but
also acquire the ability to weakly interact with CXCR4.  Eventually, a variant that can use
both CCR5 and CXCR4 is established in the population.  The abundance of CXCR4
expressing cells is higher and thus, it is plausible that with the availability of higher levels of
CXCR4 expressing cells, the variants can adapt to using CXCR4.  The use of CXCR4 comes
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with the cost of losing CCR5 binding, generating a true X4-monotropic variant.  It must be
emphasized that these mutations are not contained to V3, there is evidence that regions of the
V3 base and the gp120 bridging sheet also acquire mutations that alter the ability of Env to
interact with its coreceptor.  Our model (Fig. 5.1) suggests multiple factors in coreceptor
switching: (1) V3-specific mutations that are advantageous for X4-tropism manifest
themselves in the population, other mutations involved in the coreceptor switch are also
generated throughout env; (2) there is in vivo evolution from R5-monotropism to dual-
tropism to X4-monotropism; (3) there is an expansion of the number of V3 variants during
the dual-tropic phase, suggesting that only highly fit env variants are able to out-compete
others to establish themselves as an X4-tropic variant; (4) X4–tropic variants infect naïve T
cells and are not competing with R5-tropic viruses, giving them a selective advantage so that
the X4-tropic virus only has to replicate fast enough to allow virus spread before the cell is
killed by cytotoxic T lymphocytes; (5) the low fitness, difficult evolutionary pathway, low
affinity coreceptor interaction, low replication and low transmissibility all point to CXCR4-
tropism as a non-productive pathway and (6) coreceptor prediction tools that often include
genotypic assessment of V3 amino acid sequence are not yet powerful enough to predict
coreceptor usage because they do not account for mutations that can occur throughout env,
and they cannot account for the evolutionary variants that are dual-tropic (which may contain
signature sequences associated with both R5- and X4-tropism).
The newest clinical therapies are directed to cell-free virus in the form of entry inhibitors,
therefore, the V3-coreceptor interaction is an important interaction to understand.  The
underlying question in order to administer the correct therapeutic to individuals is the
coreceptor phenotype present in vivo.  This study concludes that genotype prediction tools
102
can be useful to initially predict V3 phenotype, but ultimately a phenotype test is required to
definitively characterize coreceptor usage.  Much more data need to be accumulated before
sequence-based predictions will be more robust, although both phenotype and genotype are
likely to find a place in clinical management as we learn how to use these tools.
In Chapter 4, we changed the focus of sequence and structure studies to the gp41
subunit of Env.  We have identified a substitution at a position that is highly conserved in the
membrane-proximal external region (MPER) of gp41.  This S668G mutation causes local
structural disruption of the MPER region, so that the virus is still infectious but hyper-
sensitive to neutralizing antibodies with epitopes in this region.  The perturbation in structure
is very restricted, binding of the inhibitors/antibodies T-20, TAK-779, and 2G12 is not
altered.  This mutation is an example of naturally occurring restriction of HIV-infectivity.
Currently, much effort is being focused on the generation of neutralizing antibodies as part of
an all-inclusive vaccine.  The design of an Env immunogen will be much improved with the
inclusion of insertions/deletions and/or substitutions that make Env more susceptible to
generation of antibodies, with the presence of Gly 668 in the MPER region of gp41 as an
example of a candidate.
5.2 PITFALLS OF CURRENT DATA AND TECHNIQUES
Some critical advancements in HIV-1 research during the last five years include
resolution of the crystal structure of the gp120 core bound to CD4, description of the cellular
restriction factors APOBEC3G and TRIM5alpha, characterization of the depletion of gut-
associated CD4+ T cells during the acute phase of infection, determination of the origins of
HIV-1, and generation of new classes of drug therapies that target HIV-1 entry.
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Fig. 5.1. Model of in vivo mutation dependent coreceptor switching
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Chapter 2 discusses the discrepancies between subtype B and subtype C Envs.  Many
differences are apparent, including the lack of binding of subtype B elicited V3 mAbs to
subtype C Env.  The reciprocal experiment to determine if subtype B V3 is, in fact, more
flexible and could bind subtype C elicited antibodies was impractical because this reagent is
not readily available.  The availability of subtype C reagents would expedite studies of the
differences in the subtypes, especially knowing that subtype C is the most prevalent subtype
worldwide.
Characterization of HIV-1 Env sequence and structure and the contribution of both to
coreceptor tropism and neutralization sensitivity have been productive, however, the answer
is never sufficient, and, more often than not, another question arises.  This can mostly be
attributed to the highly adaptive nature of the Env protein that is central to HIV-1 infectivity,
capable of generating a new env variant with every replication cycle.  The low fitness
associated with new variants is hardly surprising, although subsequent mutations can
compensate for fitness loss (documented both in vivo and in vitro).  Thus, the difficulty in
studying env is multi-faceted; on the one hand there are overwhelming numbers of env
variants to study, making cross-comparison of different studies difficult.  However, if one
env variant or clone were used for widespread research (especially in evolutionary studies), it
would not be representative of env diversity.  Use of the same env for widespread study is
encouraged to enable cross-comparison of different studies, however the in vivo relevance to
env variants is lost.  This was clearly demonstrated by our earlier attempt to characterize the
mutations associated with coreceptor switching by using site-directed mutagenesis to recreate
mutations associated with X4-tropism in the R5-tropic JR-FL env clone.  The parental (and
resulting) viruses all used CCR5, and no mutant acquired the ability to use CXCR4 in any
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measurable quantity, even with multiple mutations.  Thus, the use of subject-derived env
genes is of importance to establish relevance in vivo.
The use of a consensus or ancestral sequence for widespread study also makes sense
at a glance, encompassing env diversity and phylogenetic relationships between known env
genes.  However, this too is problematic in that one env cannot possibly be used to accurately
substitute for genetically diverse env genes.  Finally, use of either sequence or
structure/function without consulting the other will be detrimental to further research, since
the association of the two is clearly evident.  With the advent of HIV-1 single genome
amplification techniques, it is difficult to ignore the issue of PCR recombination that is likely
have some bearing on interpretation of previous studies.
To begin to address these issues, the use of single genome amplification to generate
env genes should be used as a standard for any env study that involves characterizing of
subject-derived virus.  The issue of a single Env that is best suited for cross-comparison of
research is more complicated, but the use of subject-derived samples should be advocated
since lab isolates do not encounter the same environment or selective pressures as those in
vivo.
In addition there should be more widespread study of env genes from different
subtypes to make sure generalizations are not made that do not hold true across subtypes.  An
obvious example of this is the coreceptor switch motifs and its associated rules (the 11/25
rule, the net charge rule), which only hold true for subtype B.
Finally, we should take a lead from scientists who have grouped together in a
concerted effort to understand and attempt to standardize all aspects of HIV-1 research and
ultimately design of a HIV vaccine.
106
5.3 POTENTIAL QUESTIONS IN HIV-1 ENV RESEARCH
The projects described in this dissertation have allowed us to understand, to some
extent, the impact of sequence on (1) V3 structure, function and coreceptor usage and (2)
global Env structure and neutralization sensitivity.  Future research in these areas should
characterize the ability HIV-1 Env to interact with and adapt to its environment without
being overcome by the host immune system.
Chapter 2 begins to address the issue of env diversity between two subtypes.  Subtype
C HIV-1 is most prevalent in the world, and most research is still focused on subtype B.  It is
apparent from the experiments described in Chapter 2 that these two subtypes are different
within the 35 amino acid V3 region.  What other differences are present in the biology of the
remaining 10kb genome?  There are some data starting to describe the differences, but if the
goal is to understand the overall biology of Env, different subtypes will need to be
considered.  Biological differences in V3 coreceptor usage by subtype C would benefit from
a study similar to Chapter 3, where in vivo subtype C env coreceptor evolution can be
characterized, especially with the lower occurrence of coreceptor switching.   Based on our
current observations, either subtype C evolution characterization may provide evidence of the
high fitness of virus throughout subtype C infection (preventing the need to change
coreceptor), or a high rate of mutation in the backbone env sequence.  Non-canonical
sequences in the subtype C V3 region have been recorded in those variants found to use X4,
perhaps a more thorough analysis would show a relatively increased number of substitutions
in the env backbone compared to subtype B.  This would provide answers for much needed
resolution of the coreceptor switch inconsistency between these two subtypes (and perhaps
other subtypes that also have a lower occurrence of coreceptor switch).
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Immediate questions that became evident from Chapters 2 and 3 are the notable
effects of backbone env sequence on V3.  The backbone contributes to the biological
function of V3, whether the backbone is from a different subtype, or from another intra-
subject variant.  The cloning of a replicating virus (of subtype B or subtype C descent?) with
the subtype B backbone-subtype C V3 env, and vice versa, and subsequent passaging in
increasing amounts of CXCR4 expressing cells might provide some answers.  The hypothesis
follows that there will be a larger accrual of mutations in the backbone of subtype C
backbone-subtype B V3 env compared to the subtype B backbone-subtype C V3 env due to
the larger contribution of the subtype B backbone sequence to V3 structure.  Other groups
have further described how V1/V2 is able to mask other areas of Env until CD4 binding
occurs – is the V1/V2 in subtype C comparable in that it can shield gp120?  All of these
questions will help us understand the intricate differences in Env biology between subtype B
and C.
Finally, with some more questioning the complexity of env coreceptor switching in
vivo may be understood, and the ever-present question of the relationship between coreceptor
switching and CD4+ T-cell loss may finally be answered.  To address the model proposed in
Figure 5.1, the questions that remain to be answered are:
1. Neutralization sensitivity changes throughout the course of disease progression, forcing
escape mutations.  Do Env glycosylation patterns change through disease progression?
At the late X4-tropic stage of disease, is neutralization sensitivity relatively high (dead-
end pathway), or relatively low (can efficiently replicate and be transmitted to a new
host)?
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2. What are the differences in replication between dual-tropic, early X4-tropic and late X4-
monotropic virus, measured in the same subject?  Is X4-tropism truly a dead-end
pathway?  Do X4-tropic variants need to compensate for reduced affinity for coreceptor
and bind CD4 more tightly?
3. Current methods may not be sensitive enough to detect the variants, or measure
coreceptor usage - how can detection of minor R5 or X4-tropic env populations in vivo at
the chronic stage of disease be improved?
The HIV-1 Env is the only target for neutralizing antibodies, and is the focus of
new HIV-1 therapeutics.  A sound understanding of Env will be instrumental in
decisively designing new immunogens and/or therapeutics to reduce the burden of HIV-1
disease worldwide.
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